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INTRODUCTION 
 
The Biological bases of Cancer 
 
Cancer is basically a large group of disease that can affect different part of the body [Nokhandani, 2015]. 
This might seem a very generic definition but correctly depicts the current state of our largely incomplete 
knowledge of the biology of this disease, which in turn demystify the idea of "a cure for cancer" [Simon, 
2013]. 
Indeed, to gain more information concerning the still elusive biological bases of cancers current efforts 
are focused in particular towards a systems biology approach. Indeed, among several “systems” 
approaches, “omics” technologies are reaching competitive prices and the mechanistic description of 
biological systems through these methodological tools is increasing rapidly. We are entering a research 
age characterized by digital devices able to collect "big (personal) data” which are likely to detect 
alterations in biological networks parameters that might eventually predict when an organ will become 
diseased or when a perturbation in a biological network could progress to a disease state. Therefore, the 
most promising way for a treatment or prevention of cancer (and many other conditions) will be 
personalized predictions and personalized treatments [https://www.systemsbiology.org/research/p4-
medicine/] 
 
Despite the complexity and heterogeneity of these class of diseases, there are features that commonly 
characterize all cancers (depending on the specific staging) and altogether are classically referred to as 
the hallmarks of cancer [Hanahan, 2000]. 
 
The most important trait of cancer cells is their ability to sustain uncontrolled proliferation. At the 
molecular level, one of the strategy used to achieve this feature is the overexpression of growth factors, 
either by cancer cells themselves or by the surrounding stroma [Bhowmick, 2004].  As an alternative, 
receptor signaling can be de-regulated by the overexpression of receptor proteins or by the constitutive 
activation of signaling pathways operating downstream of these receptors [Lemmon, 2010]. 
 
A second hallmark of tumor cells is their ability to evade programs that negatively regulate cell 
proliferation. Many of these programs depend on the action of tumor suppressor genes. The two 
prototypical anti-oncogenes encode the retinoblastoma (RB) and the TP53 proteins, which operate within 
the regulatory circuits that govern the decision of a cell to proliferate or, alternatively, activate senescence 
and apoptotic death programs [Sherr, 2002]. 
 
Another common feature of tumor cells is the ability to escape programmed cell death (apoptosis), which 
is a natural barrier to cancer development. Cancer cells have evolved several different strategies to 
circumvent apoptosis, the most common being loss of the critical damage sensor TP53 gene, but the same 
result may be achieved by either overexpressing anti-apoptotic regulators (Bcl-2, Bcl-xL) or 
downregulating pro-apoptotic factors (Bax, Bim, Puma) [Evan, 1998]. 
 
Cancer cells also require unlimited replicative potential in order to generate tumors. Normal cells are able 
to carry out only a limited number of divisions and then enter senescence. The immortalization of tumor 
cells is achieved through several mechanisms and among them there is the ability to maintain telomeric 
DNA at lengths sufficient to avoid triggering senescence or apoptosis; this is achieved by upregulating 
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expression of telomerase or, less frequently, by an alternative recombination-based telomere 
maintenance mechanism [Shay, 2000]. 
 
Moreover, like normal tissues, tumors require nutrient and oxygen supplies as well as the ability to 
eliminate metabolic wastes and carbon dioxide. Thus, during tumor progression an angiogenic switch is 
activated, causing normally quiescent vasculature to continually sprout new vessels that help sustaining 
tumor growth [Hanahan, 1996]. 
 
Tumor cells often acquire the ability to locally invade tissues and/or metastasize. Typically, alterations in 
cancer cell shape as well as in attachment to other cells and to the extracellular matrix occur in this 
context. The invasion-metastasis cascade seems to involve discrete steps: local invasion; intravasation 
into nearby blood and lymphatic vessels; transit through the lymphatic and hematogenous systems; 
extravasation, micrometastases formation and colonization with development of macroscopic tumors 
[Talmadge, 2010]. 
 
More recently, two other distinctive characteristics of cancer cells have been proposed as emerging 
hallmarks [Hanahan, 2011]. The first involves reprogramming of cellular energy metabolism in order to 
support continuous cell growth and proliferation. The second involves active evasion by cancer cells from 
attack and elimination by immune cells [Hanahan, 2011]. 
 
Cancer has been studied as a clonal disease for many decades [Nowell, 1976] and the first theory 
introduced to explain its onset was the somatic mutation theory (SMT). According to this theory, cancer 
is the product of the accumulation of genetic lesions progressively selecting for the fittest (generally faster 
growing) cell clones. In support of this theory, a lot of known carcinogenic chemicals were found to be 
mutagenic. Moreover, tumors are characterized by aberrant transcriptional profiles and gain/loss of 
function mutations, both involving key regulatory genes (oncogenes/oncosuppressor genes) [Hanahan, 
2011]. 
 
Although genetic aberrations represent a common feature of late-stage cancers, it is still largely debated 
whether mutations are the leading cause or just represent a side effect of carcinogenesis. Indeed, 
considering the rate of naturally occurring mutations and the large number of genetic and epigenetic 
changes that could in principle initiate and promote tumor development, cancer should paradoxically be 
ranked as a relatively rare disease, and cancer resistance rather that cancer occurrence might be worth 
investigating [Klein, 2007]. 
The recent advent of new technologies allowed a better understanding of multicellular systems and the 
heterogeneous nature of tumors is now recognized. Thus, cancer is now commonly viewed and 
analyzed as an evolving ecosystem [Gatenby, 2014] where, just like in any ecosystem, cancer cells engage 
in heterotypic interactions with cells in their microenvironment and use the available resources 
to proliferate and survive [Egeblad, 2010].  
Within this framework, generally referred as tissue organization field theory (TOFT), most of the cancer 
research is now performed in order to provide new therapeutic solutions. 
According to TOFT carcinogenesis acts initially by disrupting the normal interactions that take place among 
cells which compose the stroma and parenchyma of an organ [Sonnenschein, 2000]. 
One of the most interesting postulate of this theory is the reversibility of the states [Clark, 1991]. 
According to this theory, the neoplastic state of a cell is due to aberrant interactions and can be reversed 
or contained by “fixing” the context (meaning the microenvironment) of the cell [Bissell, 2001].   
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The high heterogeneity within both the tumor mass and the stromal compartment is the main hindrance 
to understanding the mechanisms that govern the interactions between cancer cells and the 
microenvironment. Different cell types are known to be present in the tumor surroundings: fibroblasts 
(cancer-associated fibroblasts, CAFs), endothelial cells, pericytes, immune inflammatory cells (tumor-
associated macrophages, TAMs) and progenitor cells of the tumor stroma. All of these cells could have 
either a promoting or an inhibitory activity on tumor growth, depending on the context defined by the 
signaling networks. 
Within this framework, the detailed investigation of the molecular interplay between cancer cells and the 
tumor microenvironment is essential in order to understand cancer initiation and progression, as well as 
to provide firm biological bases for new therapeutic solutions in cancer treatment. 
 
Macrophages functions and polarization patterns 
 
The accumulation of leukocyte subpopulations is the hallmark of several pathological conditions [Balkwill, 
2001]. As discussed before, tumors are heterogeneous cellular ecosystems, a prominent component of 
which is represented by non-tumoral stromal cells like fibroblasts, endothelial cells and leukocytes. 
Among the latter, macrophages are the major component [Mantovani, 2002]. 
 
Macrophages represent a heterogeneous population of innate myeloid cells. They are found in all tissues 
and present a high variability in term of transcriptional profiles. Like other immune cells, they are 
characterized by high plasticity and tend to change their expressional profile based on the stimuli received 
from the environment. [Mantovani, 2005] 
Their main function is to respond to pathogens and modulate the adaptive immune response through 
antigen processing and presentation, but they are also involved in the induction and resolution of 
inflammation, as well as tissue repair [Mosser, 2008]. 
 
The cytokine interleukin (IL)-4 was found to induce different effects on macrophage gene expression 
compared with the induction triggered by interferon (IFN)-gamma and lipopolysaccharide (LPS). In 
contrast to the classical "activation" pathway (induced by bacterial infections) of macrophages by IFN-
gamma [Nathan, 1983], the macrophage gene expression induced by IL-4 was described as “alternative 
activation” [Stein M et al. 1992]. 
 
A few years later, Mills et al. proposed a new classification of macrophages as either M1 or M2. This 
terminology originated from an observation of differential macrophage arginine metabolism in various 
mouse strains with T helper type 1 (Th1) (C57BL/6 mice) and T helper type 2 (Th2) (Balb/c mice) 
backgrounds. Th1 mice with T cells producing mostly IFN-gamma showed a macrophage activation pattern 
in which nitric oxide (NO) was generated from arginine, versus ornithine production from Th2 mice with 
T cells producing IL-4 and tumor growth factor (TGF)-β 1 [Mills, 2000]. This finding led to a consensus 
within the scientific community that M1 (classically activated) macrophages exhibit inflammatory 
functions, whereas M2 (alternatively activated) macrophages exhibit anti-inflammatory functions. 
 
In summary, the M1 macrophage phenotype is characterized by the production of high levels of pro-
inflammatory cytokines, an ability to mediate resistance to pathogens, strong microbicide properties, high 
production of reactive nitrogen and oxygen intermediates, promotion of Th1 responses and cancer 
suppression. In contrast, M2 macrophages are characterized by their involvement in parasite control, 
tissue remodeling, immune regulation, tumor promotion and efficient phagocytic activity. 
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More recently, other authors expanded the M1-M2 definitions to account for different activation 
scenarios. According to this revised view, different mediators can be used in order to produce "polarized 
macrophages" and the classical M1 (INF-gamma + LPS) and M2 (IL-4) states represent just two prototypic 
cases within a spectrum of possible activation profiles that cannot be easily binned into defined groups 
[Stout, 2004; Mantovani, 2005; Edwards, 2006; Biswas, 2010; Martinez, 2014]. 
In experimental research (especially for in vitro systems) such poorly defined classification criteria to 
describe the real scenario of macrophages polarization represent a clear limitation. 
In general, given that diverse mediators may be used alone or in various combinations for the generation 
of polarized macrophage populations, the recommendation is to adopt a nomenclature linked to the 
activation standards, i.e., M (IL-4) and M (IFN-g + LPS) instead of M2 and M1. Such nomenclature avoids 
the uncertainty of the classical definition, where one laboratory might experimentally define activation 
differently than another, and allows new activation conditions to be compared and contrasted 
with prototypical examples [Murray, 2014]. 
 
The role of macrophages in cancer 
 
Macrophages derived from monocyte precursors undergo specific differentiation depending on the local 
tissue environment. In particular, they respond to environmental cues such as damaged cells, activated 
lymphocytes, or microbial products, to differentiate into distinct functional phenotypes [Mantovani 
2002]. 
The first evidence of leukocyte infiltration into malignant tissue suggested that cancers arise at regions of 
chronic inflammation. In the tumor microenvironment, the specific subset of leukocyte that are 
characterized as macrophages have been called tumor associated macrophages (TAMs).  
TAMs derive from circulating monocytes and are recruited at the tumor site by a tumor-derived 
chemotactic factor CCL2/MCP-1 [Matsushima, 1999]. 
Evidence supporting a pivotal role of chemokines in the recruitment of monocytes in neoplastic tissues 
comes from the high correlation between their production and infiltration in murine and human tumors 
[Rollins, 1999]. 
The cytokine network expressed at the tumor site plays a central role in the orientation and differentiation 
of recruited mononuclear phagocytes, thus contributing to direct the local immune system away from 
anti-tumor functions [Mantovani, 2002]. This idea is supported by both pre-clinical and clinical 
observations [Mantovani, 2004] and clearly demonstrate an association between macrophage 
number/density and prognosis in a variety of murine and human malignancies. 
The immunosuppressive cytokines IL-10 and transforming growth factor (TGF)-β are produced by both 
cancer cells and TAMs [Mantovani, 2002]. IL-10 promotes the differentiation of monocytes to mature 
macrophages, blocks their differentiation to dendritic cells (DC) [Allavena, 2000] and promotes the 
alternative pathway of macrophage activation inducing TAMs to express M2-related functions.  
Altogether, the production of IL-10, TGFβ and prostaglandin E2 (PGE2) by cancer cells and TAMs 
[Mantovani, 2002] contributes to a general suppression of anti-tumor activities. 
TAMs are poor producers of NO [Dinapoli, 1996] and, in contrast to M1 polarized macrophages, have been 
shown to be poor producers of reactive oxygen intermediates (ROIs) [Klimp, 2001]. 
 
Angiogenesis is another M2-associated function, which represents a key event in tumor growth and 
progression. In human cervical cancer it has been proposed that VEGF-C production by TAMs play a role 
in peri-tumoural lympho-angiogenesis and subsequent dissemination of cancer cells with formation of 
lymphatic metastasis [Schoppmann, 2002]. Additionally, TAMs participate to the pro-angiogenic process 
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by producing the angiogenic factor thymidine phosphorylase (TP), which promotes endothelial cell 
migration in vitro and whose levels of expression are associated with tumor neovascularization [Hotchkiss, 
2003].  
 
Finally, TAMs express molecules able to remodel the surrounding connective tissue, providing advantages 
to tumor cell proliferation and spreading. In lung cancer, TAM may favor tumor progression by 
contributing to stroma formation and angiogenesis through their release of platelet derived growth factor 
(PDGF), in conjunction with TGF-β1 production by cancer cells [Mantovani, 2002].  Macrophages can 
produce enzymes and inhibitors that regulate the digestion of the extracellular matrix, such as matrix-
metalloproteases (MMPs), plasmin, urokinase-type plasminogen activator (uPA) and the uPA receptor. 
Direct evidence has been presented that MMP-9 derived from hematopoietic cells of host origin 
contributes to skin carcinogenesis [Coussens 2000]. 
In summary, under many aspects TAMs display a number of functions expressed by M2 macrophages, 
involved in tuning inflammatory responses and adaptive immunity, scavenge debris, promote 
angiogenesis, tissue remodeling and repair [Locati, 2002]. 
 
Although TAMs and their relationship with tumor cells have been extensively studied, several experiments 
have demonstrated that macrophages have the potential to kill tumor cells in vitro when appropriately 
stimulated.  
Solid tumors establish physical/chemical barriers to prevent entry of immune cells in order to escape from 
immune surveillance, but TAMs (which represent a component of the stroma and are usually there to 
assist tumor progression) may be the target of a re-education from a tumor-supportive phenotype to a 
tumor-suppressive phenotype [Wang, 2017].  
Recent studies which used cells or microspheres as biological vectors to deliver therapeutic molecules 
specifically to the neoplastic site made some significant effects.  In a metastatic prostate cancer animal 
model, intratumoral injection of macrophages transduced with IL-12 recombinant adenovirus vector led 
to the reduction of primary prostate cancer growth and lung metastases [Satoh, 2003].  
IL-12 is a key immunoregulatory cytokine, it is produced mainly by antigen-presenting cells and can 
regulate innate responses [Breading, 2006]. IL-12 determines the type of adaptive immune responses 
during infection triggering CD4-T cells to differentiate into Th1 cells which in turn stimulate the classical 
activation of local macrophages [Hamza, 2010]. 
 
To conclude, a high M1/M2 ratio has been reported to be associated with an improved survival in solid 
tumors [Pollard, 2008]. Nevertheless, bacterial stimuli and Th1 cytokines inducing M1 type polarization 
are usually not present at the tumor site. Here, in contrast, differentiating macrophages are likely to 
encounter factors that most frequently polarize them toward M2 type macrophages.  
Therefore, the manipulation of the tumor microenvironment aimed to the re-education of TAMs may 
have promising applications in the field of tumor immune therapy. 
 
The role of the RNASET2 gene in cancer  
 
Loss of heterozygosity (LoH) studies have long been used as powerful tools to obtain molecular evidence 
for the subchromosomal localization of putative human tumor suppressor genes (TSGs). 
In this context, LoH studies carried out in the last decades on ovarian tumors and ovarian cancer cell lines 
have consistently reported chromosomal loss on human chromosomes 1, 6, 9, 10 and 11 for this cancer 
type [Nakayama, 2007; Tapper, 1997; Suehiro, 2000]. Particularly, three different consensus regions of 
LoH in human chromosome 6 were identified: 6q21-23.3 [Orphanos, 1995], 6q25.1-25.2 [Colitti, 1998] 
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and 6q.26-27 [Saito, 1992; Tibiletti, 1996]. The human RNASET2 gene maps within the latter chromosomal 
region. RNASET2 is a 27 kb single-copy gene composed by nine exons and eight introns [Tibiletti, 1998] 
and coding for the unique human member of the extracellular Rh/T2/S ribonuclease gene family. 
Ribonucleases represent a wide family of enzymes able to process or degrade ribonucleic acids. 
Historically, investigations have focused on ribonucleases belonging to the RNase A family members, 
which are limited to vertebrate species [D’Alessio; 1997]. However, a growing interest has been recently 
focused on the highly conserved Rh/T2/S RNAse family [McClure, 1990], due to their very high 
evolutionary conservation and their involvement in several key cellular and biological processes, such as 
nutritional stress response [Liang, 2002], neural development [Henneke, 2009], modulation of the 
immune response [Steinfelder, 2009], cell death [Thompson, 2009], cancer growth control [Acquati, 2011, 
2013] and stress response [Lualdi, 2015], to name a few. 
 
The human RNASET2 protein is composed by 256 amino acids and its primary sequence reveals the 
presence of three distinct protein segments: a signal peptide for secretion at the N-terminus (aa. 1-24), a 
central core that undergoes N-glycosylation and carries the two conserved active-site segments (CASI and 
CASII) responsible for the catalytic activity of the protein and a C-terminal de-structured portion 
[Campomenosi, 2006]. 
The RNASET2 protein is commonly detected in three different intracellular isoforms: a full-length 36 kDa 
form, which is secreted in the extracellular space, and two 31 and 27 kDa isoforms, which originate from 
proteolytic cleavage at the C-terminus of the full-length protein. By sub-cellular fractionation assays, both 
31 and the 27 kDa isoforms were detected in the lysosomal fraction. This observation is consistent with 
the hypothesis of a functional role of RNASET2 as an acid ribonuclease in the acid lysosomal compartment 
[Campomenosi, 2006]. Moreover, localization of RNASET2 protein in processing bodies (P-bodies) has also 
been reporter under stress condition [Vidalino, 2012].  As for the ribonuclease activity of RNASET2 protein, 
it shows a base preference for poly-A and Poly-U synthetic polynucleotides, with respect to Poly-G and 
Poly-C, at pH 5.0 [Campomenosi, 2006]. 
 
Because of the chromosomal location of the human RNASET2 gene in a region frequently rearranged in 
tumors, its putative tumor suppressive role has been thoroughly investigated in recent years. 
Using the ovarian carcinoma as an experimental model, no mutations were found in the coding sequence 
of the RNASET2 gene in human primary ovarian tumors and tumor cell lines [Acquati, 2001]. However, 
RNASET2 down-regulation at the mRNA level was reported in both primary ovarian tumors and ovarian 
tumor cell lines, with respect to normal tissue/cells. In order to understand the molecular bases of the 
lower RNASET2 expression levels in tumors, a promoter methylation analysis was performed, but no 
significant differences in promoter methylation were reported between tumor and normal samples, 
suggesting that other epigenetic mechanisms could be responsible for RNASET2 hypoexpression in tumors 
[Acquati, 2001]. 
 
However, a marked RNASET2-mediated tumor suppression in vivo has been demonstrated using both 
ovarian carcinoma and malignant melanoma as experimental models. Indeed, RNASET2-overexpressing 
tumor clones turned out to be strongly suppressed in their tumorigenic and metastatic potential after 
injection in immunodeficient mice [Acquati, 2001]. 
On the basis of this evidence, RNASET2 was defined as a class II tumor suppressor gene, being 
hypoexpressed in tumors despite the absence of structural alterations in the sequence of the gene. 
 
To address the role of the catalytic activity of RNASET2 protein in the observed in vivo tumor suppression, 
Hey3Met2 ovarian tumor clones overexpressing a catalytically inactive form of the protein were 
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generated. The catalytically-dead form of the protein was obtained by replacement of the two key 
Histidine residues in CAS sites (H65 and H118) with two Phenylalanine residues. 
Strikingly, RNASET2-mediated tumor suppression turned out to be independent of the ribonuclease 
activity of the protein. Indeed, using xenograft models in nude mice, RNASET2 H65/118F-overexpressing 
Hey3Met2 clones resulted to be suppressed in their tumorigenicity as well as their RNASET2 wild type-
overexpressing counterpart [Acquati, 2005]. 
 
Moreover, a close histological examination of xenograft tumors sections revealed a consistent infiltrate 
of host cells in tumors derived from RNASET2-overexpressing Hey3Met2 clones. Analysis with specific cell-
surface markers demonstrated that the infiltrate was mainly due to cells belonging to the monocyte-
macrophage cell lineage [Acquati, 2011]. In the same direction, inoculation of nude mice with human 
ovarian cancer-derived cells with high endogenous RNASET2 expression levels (OVCAR3) led to the 
development of small, growth-suppressed tumors, characterized by a strong infiltrate of host-derived 
innate immunity cells, which have been identified as M1 polarized macrophages. By contrast, RNASET2-
silenced OVCAR3 cells developed large, fast-growing tumors with no sign of macrophage infiltration 
[Acquati, 2013]. 
 
To further investigate the role of the monocyte-macrophage cell population in the RNASET2-mediated 
tumor suppression, a new experimental in vivo model was exploited, in which the monocyte-macrophage 
lineage was depleted by clodronate treatment in RAG-γ chain mice. In this model, RNASET2-mediated 
tumor suppression activity was drastically impaired in clodronate-treated mice when compared to 
untreated control mice [Acquati, 2011].  
Finally, the involvement of RNASET2 in the recruitment of cells belonging to the monocyte linage has been 
also assessed in vitro; by these assays, recombinant RNASET2 protein displayed a marked chemotactic 
activity in vitro, possibly dependent from a subfamily of GPCR associated with inhibitory G protein 
[Acquati, 2013]. 
Taken together, these data suggest that the tumor microenvironment and particularly the monocyte-
macrophage cell population seems to play a crucial role in RNASET2-mediated tumor suppression in 
vivo. 
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AIMS OF THE PROJECT 
 
The RNASET2 gene encodes for the only human secreted acid ribonuclease of the T2 family. This gene 
maps to human chromosome 6q27, a region that is consistently found rearranged in many solid and 
hematological tumors [Acquati, 2005]. Experimental data have demonstrated the role of RNASET2 as a 
tumor suppressor gene which is endowed with several functions including chemotactic and possibly 
activating activity toward the monocyte/macrophage population [Acquati, 2011]. 
In a mouse xenograft model, we have recently reported that inoculation of human ovarian cancer-derived 
cells forced to overexpress RNASET2 led to the development of small, growth-suppressed tumors, 
characterized by a strong infiltrate of host-derived innate immunity cells, which have been identified as 
M1 polarized macrophages. By contrast, control cells expressing RNASET2 at lower level (or silenced by 
RNA interference), developed large, fast-growing tumors with no sign of macrophage infiltration. 
Further investigations proved that recombinant RNASET2 (produced with both baculovirus and Pichia 
pastoris expression system) displayed a marked chemotactic activity in vitro, possibly dependent from a 
subfamily of GPCR associated with inhibitory G protein [Acquati, 2013]. 
Taken together, these results led us to suggest that the observed in vivo tumor suppression is a non-cell-
autonomous effect based on RNASET2-mediated recruitment of macrophages into the tumor mass. 
Based on these experimental data, we decided to further investigate the functional implications of the 
interaction between RNASET2 and the monocyte-macrophages, following different approaches as 
outlined below: 
 
? Since a considerable amount of protein is required to perform functional studies, we improved 
our heterologous expression systems for production and purification of endotoxin-free 
recombinant RNASET2.   
? The functional interaction of RNASET2 with innate immune cells has been investigate in an 
independent, cost-effective in vivo system represented by the leech Hirudo verbana. 
? Based on our previous in vitro data (chemotaxis and internalization assays) we hypothesized the 
occurrence of a cellular system able to “sense” extracellular RNASET2 protein. The existence of a 
putative cell surface receptor for RNASET2 was therefore investigated. 
? Our previous in vivo data showed that the stromal cell infiltrate in RNASET2-expressing tumors 
was represented by M1-polarized macrophages. The role of recombinant RNASET2 in macrophage 
differentiation and polarization was therefore investigated. 
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MATERIALS AND METHODS 
 
Reagents and media 
The EasySelect™ Pichia Expression Kit was available from Invitrogen (Thermo Fischer Scientific, Waltham, 
MA, USA). Phusion® High-Fidelity DNA Polymerase and restriction/modification enzymes were from New 
England Biolabs (NEB, Ipswich, MA, USA). Zeocin was purchased from InvivoGen (InvivoGen, Toulose, 
France). Yeast Nitrogen Base from Difco BD (Becton Dickinson and Company, Franklin Lakes, NJ, USA). 
Bradford reagent and Polyprep columns were from Bio-Rad (Bio-Rad laboratories, Hercules, CA, USA). 
Ultrafree centrifugal concentrators (5 kDa MWCO) were from Merck Millipore (EMD Millipore, Billerica, 
MA, USA), VivaFlow 50 cross flow cassettes (10 kDa MWCO) from Sartorius (Sartorius AG, Gottingen, 
Germany), Slide-A-Lyzer dialysis cassettes (10 kDa MWCO) from Thermo Scientific (Thermo Fischer 
Scientific, Waltham, MA, USA). Ni-NTA resins were obtained from Qiagen (Qiagen N.V., Venlo, 
Netherlands); HisTrap HP (1 ml), HiTrap Q HP (1 ml) and Superdex 75 10/300 GL columns were from GE 
Healthcare (General Electric Co., Fairfield, CT, USA). NuPAGE Bis-Tris precast gels were from Life 
Technologies (Thermo Fischer Scientific, Waltham, MA, USA), nitrocellulose and PVDF membranes were 
from GE Healthcare (General Electric Co., Fairfield, CT, USA). SuperSignal® West Dura Extended Duration 
Chemiluminescent Substrate was available from Thermo Scientific (Thermo Fischer Scientific, Waltham, 
MA, USA). All other reagents were from Sigma-Aldrich (Sigma-Aldrich Corporation, St. Louis, MO, USA), 
unless otherwise stated. 
 
Cloning of the human RNASET2 coding sequence in plasmid vectors 
Cloning of the wild-type (wtRNASET2) RNASET2 coding sequences, fused at the 3'-end to sequences 
coding for both HA (hemagglutinin) and 6xHistidine tags into the pPICZαA expression vector, have been 
described previously (pPICZαA-wtRNASET2 and pPICZαA-RNASET2 H65/118F [Campomenosi, 2011]. In 
order to improve the efficiency of the purification steps we decided to clone the wild-type RNASET2 
coding sequence with an additional 6xHis tag at the 5’-terminus (pPICZαA-wt2tag RNASET2). The pPICZαA-
wtRNASET2 construct was used as a template for a PCR reaction with the following primer pair (5'-3'): 
RNASET2 fw Eco6XHis 25aa: ACTGGAATTCCATCACCACCATCATCACGACAAGCGCCTGCGTGAC 
3’AOX rev: GCAAATGGCATTCTGACATCC 
The amplification product was digested with EcoRI and XhoI, gel purified and cloned into pPICZαA before 
transforming in the DH5α E. coli strain. Plasmid DNA was purified and, after sequencing (BMR, Padova, 
Italy), the empty vector and pPICZαA-wt2tag RNASET2 construct were used to transform X33 P. pastoris 
strain. 
 
Transformation of P. pastoris and "methanol utilization" phenotype screening 
RNASET2-coding construct or empty vector were linearized within the 3'AOX region with PmeI restriction 
enzyme and transformed into P. pastoris by the lithium chloride method [Gietz, 1995]. The methanol 
utilization plus (Mut+) X33 strain was transformed. Transformants were selected on Yeast Extract Peptone 
Dextrose (YPD) plates (1% yeast extract, 2% bactopeptone, 2% dextrose, 20 g/l bactoagar) containing 100 
µg/ml Zeocin and confirmed by streaking on the same plates. Zeocin-resistant clones were picked and 
lysed by boiling at 100°C for 10 min. PCR reactions were performed on lysates according to manufacturer's 
instructions in order to discriminate integration of the empty vector from integration of RNASET2-
containing constructs. Mut+ strain colonies positive for integration were also screened for the methanol 
utilization phenotype by streaking on MDH and MMH plates (Minimal Dextrose Histidine and Minimal 
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Methanol Histidine: 1,34% yeast nitrogen base, 4x10-5% biotin, 0.004% histidine, 15 g/l bactoagar and 
either 2% dextrose for MDH or 0.5% methanol for MMH plates). 
 
 
Expression of RNASET2 in P. pastoris 
Buffered complex glycerol or buffered complex methanol (BMGY/BMMY) (1% yeast extract, 2% 
bactopeptone, 1,34% yeast nitrogen base, 4x10-5% biotin and either 1% glycerol or 0.5% methanol) media 
were used to grow cells and analyze the expression of RNASET2. Briefly, selected clones were plated and 
grown for 3 days at 28°C. One colony was picked and inoculated into 50 ml of BMGY medium. Cultures 
were grown at 28°C overnight until they reached an Optical Density at 600 nm (OD600) between 2 and 6. 
They were then centrifuged and the cell pellet was resuspended in BMMY at a starting OD600 of 1 for 
induction of protein expression. Fresh methanol (0.5% final concentration) was added to the culture each 
day, from time 0 to 7 days from the first induction. 
 
Purification of RNASET2 from P. pastoris supernatants by IMAC 
Cell cultures were processed after 7 days from induction and the best producer clone was selected to 
express the protein for subsequent purification. After pelleting the cells at 2500 g in a swinging bucket 
rotor, the supernatant was filtered (0.45 µm) and processed. 
Gravity-flow affinity chromatography. Conditioned media were concentrated (10 kDa cut-off) and then 
incubated with the Ni-NTA Agarose matrix, in the presence of 10 mM imidazole (Qiagen). Post-binding 
the mixtures (medium/resin) were poured into columns. The flow-through, wash (50 mM imidazole) and 
eluate fractions (250 mM imidazole) were collected and analyzed by SDS-PAGE (silver staining) and 
immunoblotting. 
FPLC purification. Conditioned media (500 ml to 1l volumes) from P. pastoris cultures expressing 
RNASET2 protein were concentrated by ultrafiltration on VivaFlow 50 cross-flow cassettes (10 kDa 
MWCO) to final volumes of 20 to 50 ml. The concentrated solutions were extensively dialyzed against PBS 
(20 mM Na-Phosphate, 150 mM NaCl, pH 7.50) using Slide-A-Lyzer dialysis cassettes (10 kDa MWCO) and 
adjusted to 500 mM NaCl and 10 mM Imidazole final concentrations prior to loading onto a HisTrap HP (1 
ml) column equilibrated with PBS containing 500 mM NaCl and 10mM Imidazole (equilibration buffer). 
Retained proteins were eluted at 1 ml/min using a step gradient of Imidazole in equilibration buffer. 
Eluates from the HisTrap column were further purified by negative-mode anion exchange 
chromatography (i.e., RNASET2 proteins passed through the stationary phase and contaminants were 
retained on it). To this end, protein solutions from HisTrap were made 100 mM NaCl by dilution with 
buffer A (20 mM Tris-Cl, 100 mM NaCl, pH 7.50), then loaded onto a HiTrap Q XL (1 ml) column 
equilibrated with buffer A at 1 ml/min and eluted with a step gradient of buffer B (20 mM Tris-Cl, 1M 
NaCl, pH 7.50). Where described, aliquots of both manually (i.e., from Ni-NTA resin) and FPLC (i.e., from 
either HisTrap or HiTrap Q columns) purified proteins were chromatographed on a Superdex 75 10/300 
GL gel filtration column, using PBS as eluent at 0.5 ml/min. In all cases, chromatography columns were 
mounted onto ad operated by an ÄKTA Purifier FPLC system, and protein elution was monitored as UV 
absorbance at 280 nm. 
 
Analysis of RNASET2 expression by immunoblotting from conditioned media 
Aliquots of conditioned media from RNASET2-expressing P. pastoris cultures as well as relevant fractions 
from chromatography were separated on either 4-12% and 10% Bis-Tris or 13% Tris-Glycine gels. Proteins 
were either revealed by Silver Staining (Sigma-Aldrich) or transferred onto PVDF/nitrocellulose 
membranes. These were saturated with either PBS or Tris-buffered saline (TBS) containing 5% (w/v) non-
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fat dry milk and RNASET2 proteins were revealed with selected primary antibodies (i.e., either rabbit anti-
RNASET2 polyclonal antibody or mouse anti-His tag monoclonal antibody) followed by the appropriate 
horseradish peroxidase-conjugated anti-mouse or -rabbit IgG secondary antibody. Membranes were 
incubated with SuperSignal® West Dura Extended Duration Chemiluminescent Substrate and 
chemiluminescence recorded on a Chemidoc® MP system (Bio-Rad) or X-Ray films (Thermo Scientific). 
 
Zymographic analysis 
To verify the acquisition of the proper folding, we assess the catalytic activity of recombinant RNASET2 
protein purified from P. pastoris supernatants performing a zymographic analysis. Polyacrylamide gels 
were prepared with the addition of total RNA from Torula yeast in resolving (2 mg/ml) and stacking (0.3 
mg/ml) gel solutions. Proteins were diluted in non-reducing sample buffer (125 mM Tris-HCI pH 6.8, 2% 
SDS, 10% glycerol, 0,02% bromophenol blue) and loaded without boiling. After electrophoresis, SDS was 
removed with 25% isopropanol dissolved in wash solution (10 mM Tris-HCl, pH 7.4), then gels were 
washed extensively and incubated at 51°C in freshly prepared activity buffer (100 mM KCl, 100 mM 
Sodium acetate, pH 5.0). Enzymatic activity was detected by bleaching of the toluidine blue staining. After 
image acquisition, gels were completely destained and processed for immunoblotting. 
 
Animals and treatments 
Leeches H. medicinalis (Annelida, Hirudinea, from Ricarimpex, Eysines, France) measuring 10 cm were 
kept in water at 20 °C in aerated tanks and fed weekly with calf blood. For each experimental group, 
treatment (PBS, LPS, recombinant protein or matrigel injection) was performed at the level of the 80th 
superficial metamere on leeches anaesthetized with a 10 % ethanol solution. Treated and control 
untreated animals were anesthetized and then dissected to remove body wall tissues or matrigel pellets 
at specific time points (T24h, T7days). Animals were randomly split into eight separate 
experimental groups (five individuals for each time point) and submitted to various protocols 
and treatments. 
Group 1: control animals (uninjected) 
Group 2: control animals injected with 100 µl sterilized PBS (138 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 
1.5 mM KH2PO4, pH 7.4) and analyzed at T24 h and T7 days. 
Group 3: animals injected with 100 µl sterilized PBS containing 20ng of recombinant hRNASET2 protein 
and analyzed at T24 h and T7 days to functionally characterize cells migrating under the influence of this 
factor. The best concentration of hRNASET2 required to induce significant cell migration was determined 
based on previous works [Grimaldi, 2011]; 
Group 4: animals injected with 100 µl of sterilized PBS containing 50 ng of recombinant hRNASET2 
previously incubated for 1h at room temperature with 1µg of anti-hRNASET2 specific polyclonal 
antibody [Campomenosi, 2011] to perform antibody-mediated neutralization experiments, analyzed at 
T24 h and T7 days. 
Group 5: animals injected with 100 µl of PBS containing 100 ng/ml LPS obtained from E. coli (Serotype 
0111: B4, Sigma, St. Louis, MO, USA) in order to evaluate the expression of RNASET2 in cells involved in 
innate immune response, analyzed at T24h. 
Group 6: control animals injected with 300 µl of liquid matrigel MG (an extract of the murine Engelbreth–
Holm–Swarm (EHS) tumor produced as previously described) [Kleinman, 1986], analyzed at T7 days. 
Group 7: animals injected with 300 µl of liquid MG supplemented with 50ng of hRNASET2, were used to 
selectively isolate the cells migrating under the influence of RNASET2 and were analyzed at T7 days. 
Group 8: animals injected with 300 µl of liquid MG supplemented with 50 ng of hRNASET2 and 1µg of the 
polyclonal antibody RNASET2, used for antibody-mediated neutralization experiments and analyzed at T7 
days.  
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Optical and electron microscopy 
Leech tissues, dissected from the area of the injection, were fixed for 2 h in 0.1 M cacodylate buffer at pH 
7.4, containing 2 % glutaraldehyde. Specimens were then washed in the same buffer and postfixed for 1 
h with 1 % osmium tetroxide in cacodylate buffer, pH 7.4. After standard serial ethanol dehydration, 
specimens were embedded in an EponAraldite 812 mixture. Sections were obtained with a Reichert 
Ultracut S ultratome (Leica, Wien, Austria). Semi-thin sections were stained by crystal violet and basic 
fuchsine and subsequently observed under a light microscope (Nikon Eclipse Ni, Nikon, Tokyo, Japan). 
Data were recorded with a DS-5 M-L1 digital camera system (Nikon). Ultrathin sections were placed on 
copper grids, stained by uranyl acetate and lead citrate and observed with a Jeol 1010 EX electron 
microscope (Jeol, Tokyo, Japan). 
 
Immunohistochemistry 
Samples (leech tissues and matrigel pellets), were embedded in Polyfreeze tissue freezing medium (OCT) 
(Polysciences, Eppelheim, Germany) and immediately frozen in liquid nitrogen. Cryosections, obtained 
with a Leica CM 1850 cryotome. For a morphological view serial cryosections were stained by crystal violet 
and basic fuchsine. For immunofluorescence staining, sections, rehydrated with PBS for 5 min, were pre-
incubated for 30 min with PBS containing 2 % bovine serum albumin (BSA) before incubation (1 h at 37 
°C) with the following primary polyclonal antibody diluted in blocking solution: rabbit anti-human anti-
RNASET2 [Campomenosi , 2011], diluted 1: 200; rabbit anti-human CD68 (Santa Cruz Biotechnology, Calif., 
USA), which reacts, as previously demonstrated, with leech macrophage-like cells [de Eguileor, 2003], 
diluted 1:100; rabbit anti-H.medicinalis HmAnti-AIF-1 (specific marker for macrophages leech [Drago, 
2014] and kindly donated by Prof. Jacopo Vizioli, University of Lille 1, France, diluted 1: 1000. The washed 
specimens were incubated for 1h at room temperature with the appropriate secondary antibodies 
(Abcam, Cambridge, UK), diluted 1:200, goat anti-rabbit Cy5-conjugated (excitation filter 650 nm, 
emission filter 672 nm) or goat anti-rabbit fluorescein isothiocyanate (FITC)-conjugated (excitation 
493 nm, emission 518 nm). Double labelling experiments were performed as 
previously described [Grimaldi, 2009] 
to detect RNASET2 /HmAIF-1 or RNASET2 / CD68, RNASET2 was applied first and then sections were 
incubated with the secondary antibody, goat anti-rabbit (Cy5)-conjugated. According to Würden and 
Homberg [Würden, 1993], to inhibit binding of the primary antiserum of the second staining cycle to the 
goat anti-rabbit IgGs that were applied in the first sequence, the sections were incubated with rabbit IgG 
(Jackson ImmunoResearch) at 1:25 for 2 h. After washing the samples were incubated with the antibody 
anti HmAIF-1 or anti CD68. Subsequently, the sections were treated with the secondary (FITC)-conjugated 
goat antirabbit antibody. According to Schnell and colleagues [Schnell, 1999], 
after immunocytochemistry, the sections were treated with 1 mM CuSO4 in 50 nM ammonium acetate 
buffer (pH 5.0) for 15 min and then washed in distilled water and PBS. Application of CuSO4 for 10 minutes 
after immunohistochemistry substantially reduced tissue autofluorescence while preserving the specific 
fluorochrome signal. In all controls experiments primary antibodies were omitted and sections were 
incubated only with the secondary antibodies. Nuclei were stained by incubating for 15 min with 49,6-
Diamidino-2-Phenylindole (DAPI, 0.1 mg/ml in PBS, excitation 340 nm, emission 488 nm). The slides were 
mounted in Citifluor (Citifluor, London, UK) with coverslips and examined with a Nikon fluorescence 
microscope or with a confocal laser microscope (Leica TCS SP5). Images were combined with Adobe 
Photoshop (Adobe Systems Incorporated, San Jose, CA, USA). 
 
RESULTS 
13 
 
Protein extraction and Western blot analysis 
Extracts from tissue. H. medicinalis tissues extracted from the unstimulated body wall or from injected 
areas were immediately frozen in liquid nitrogen and then homogenized with a mortar. For SDS-PAGE, 
leech homogenates were suspended (10 µl per mg of tissue), in RIPA buffer (150 mM NaCl, 1% NP-40, 
0,5% Sodium deoxycholate, 0,1% SDS, 50 mM Tris-HCl pH 8.0) in the presence of a protease inhibitor 
cocktail (Sigma, Milan, Italy). The particulate material was removed by centrifugation at 13,000 rpm for 
10 min at 4 °C in a refrigerated Eppendorf Minispin microcentrifuge (Eppendorf, Hamburg, Germany). 
Supernatants were collected, denatured at 95 °C for 5' min and loaded on 10 % acrylamide for SDS-PAGE 
analyses. Immunoblot analysis was performed using standard procedures and detected with a 
chemiluminescent substrate (Super-signal West Dura extended duration kit, Thermo Scientific). 
Extracts from adherent/suspended cells. Adherent cells were mechanically scraped in PBS + 5mM EDTA 
and resuspended in lysis buffer (0.5% Igepal, 0.5% Triton X-100 in PBS + 5mM EDTA) supplemented with 
protease inhibitors cocktail. Suspended cells were collected, washed and resuspended in lysis buffer. 
Samples were kept 45' in a rotor stator at 4 °C; the particulate material was removed by centrifugation at 
13,000 rpm for 10 min at 4 °C and supernatants were collected and quantified with Bradford reagent 
(bovine serum albumin was used as standard). 
For the SDS-PAGE analysis, 30-70 µg of intracellular lysate were denatured at 95°C for 5' in RIPA buffer 
and loaded on 10 % acrylamide for SDS-PAGE analyses. Immunoblot analysis was performed using 
standard procedures and detected with a chemiluminescent substrate (Super-signal West Dura extended 
duration kit, Thermo Scientific). 
 
? anti-RNASET2 (Davids Biotechnologie GmbH, Regensburg, Germany). 1:500 in 5% PBS-milk for 60'. 
HRP anti-rabbit IgG (Jackson ImmunoResearch Laboratories, West Grove, USA) 1:5000 in 2% PBS-
T-milk + 0.1% SDS for 45'. 
? anti-HmAIF-1 1:5000 in 5 % TBS-milk for 60'. HRP anti-rabbit IgG 1:5000 in 5% TBS-milk for 45'. 
? anti-tubulin (Proteintech, Chicago, USA) 1:1500 in 5% PBS-milk for 60'. HRP anti-rabbit IgG 1:5000 
in 2% PBS-T-milk + 0.1% SDS for 45'. 
? anti-human GAPDH (Proteintech, Chicago, USA) 1:2000 in 5% PBS-milk for 60'. HRP anti-rabbit IgG 
1:5000 in 2% PBS-T-milk + 0.1% SDS for 45'. 
 
BS3 crosslinking 
Suspend cells at ~25 × 10^6 cells/mL in PBS (pH 8.0) and wash cells three times with ice-cold PBS (pH 8.0) 
to remove amine-containing culture media and proteins from the cells. 
Add ligands to the cells and incubate for 1 hour at 4°C. Add the BS3 solution to a final concentration of 
5mM. 
Incubate the reaction mixture for 30 minutes at room temperature. Add the Quench Solution 91M Tris-
HCl, pH 7.5) to a final concentration of 20mM Tris, incubate for 15 minutes at room temperature 
and proceed with protein extract. 
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NHS resin 
 
Functionalization. Prepare protein or peptide solution in Coupling Buffer (0.1M sodium phosphate, 
0.15M NaCl, pH 7.2) for direct addition to the desired amount of dry resin. Place an appropriate amount 
of dry NHS-Activated Agarose resin to an empty spin column and add the protein or peptide sample 
directly to the dry resin (use at least twice the sample volume to swell volume. The resin swell volume is 
6-7.5mL of wet resin per gram of dry resin. For the 33mg spin column, use 400µL of sample; for the 
330mg spin column, use 4mL of sample). Replace the top cap on the column and mix the reaction end-
over-end for 1 hour (approximately 80% of the reaction occurs in the first 30 minutes. The reaction may 
be extended to 2 hours at room temperature or overnight at 4ºC). Remove top and bottom caps and 
place the column in a collection tube. Centrifuge at 1000 × g for 1 minute and save the flow-through. 
Add Coupling/Wash Buffer (twice the volume of the resin) to the column, centrifuge at 1000 × g for 1 
minute and save the wash fraction. Repeat this step once (the saved flow-through and washes can be 
used to determine the coupling efficiency by comparing the protein concentrations of these non-bound 
fractions to the starting sample). Add Quenching Buffer (1M Tris, pH 7.4, twice the volume of the resin) 
to the column and replace the bottom cap. Replace the top cap and mix end-over-end for 15-20 minutes 
at room temperature. Remove the top cap and then the bottom cap. Place the column in a new 
collection tube, centrifuge at 1000 × g for 1 minute and discard the flow-through. Wash column with 
Coupling/Wash Buffer. Monitor the final washes for the presence of protein by measuring absorbance at 
280nm or by the Pierce 660nm Protein Assay. Either proceed directly with affinity purification or 
prepare column for storage. For storage, wash column with PBS containing 0.05% sodium azide or other 
preservative. Replace bottom cap when 0.5-1mL of buffer remains above the resin bed. Replace top cap 
and store column upright at 4°C. 
Purification. Equilibrate the prepared affinity column to room temperature. Remove top and bottom 
caps and place column in a collection tube. Centrifuge the column at 1000 × g for 2 minutes to remove 
the storage solution. Equilibrate column by adding Binding Buffer (0.1M sodium phosphate, 0.15M NaCl, 
pH 7.2) and centrifuge at 1000 × g for 2 minutes. Discard buffer from collection tube. Repeat this step 
twice. Add sample to column and allow it to enter the resin bed. Replace top and bottom caps on the 
column. Incubate the column 2 hours at room temperature with end-over-end mixing. Remove top cap 
and bottom caps from column and place column in new collection tube. Centrifuge the column at 1000 × 
g for 2 minutes. Save the flow-through to analyze binding efficiency. Wash the column with of 
Binding/Wash Buffer. Centrifuge at 1000 × g for 2 minutes. 
Elute the bound protein by applying Elution Buffer (0.2M glycine-HCl, pH 3.0). Collect fractions 
for subsequent analysis. The pH of each fraction can be adjusted to neutral by adding 50µL of 
Neutralization Buffer (1M Tris; pH 9) per 1mL of collected eluate. Pool fractions of interest and exchange 
into an appropriate storage buffer by desalting or dialysis. 
 
Cells lines 
 
All the cell lines were purchased from ATCC. Mycoplasma analysis was performed before every 
experiment. Suspension growth: U937 (human histiocytic lymphoma); THP-1 (human acute monocytic 
leukemia). Culture medium: RPMI-1640 + 10% heat-inactivated FBS + 1% L-glutamine. Culture conditions: 
37°C, 5% CO2, humidified atmosphere. 
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RNASET2 Knockdown in THP-1 Cells 
 
RNASET2 silencing was carried out by means of Nucleofector technology using a vector expressing an 
shRNA targeting nucleotides 814 to 832 within the RNASET2 mRNA (Genbank accession no. 
NM_003730.4). 
Oligonucleotide sequences for RNAi were generated with the pSicoOligomaker 1.5 software and 
subsequently aligned to the human genome sequence (UCSC Genome Browser) to test for specificity. 
Control scrambled sequences were designed having the same length and GC content as the test sequence, 
but with no significant match to the database. Sense and antisense oligonucleotides representing 
RNASET2-targeting sequence were annealed and cloned into HpaI/XhoI-digested pSicoR vector (provided 
by F. Nicassio, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy). The recombinant shRNA-
expressing vector was stably transfected into THP-1 cells with the Cell Line Nucleofector Kit V (Amaxa). 
The efficiency of RNASET2 knockdown was evaluated by Western blot analysis before every experiment. 
Cells were maintained under selection throughout all the experiments to ensure the stability of the pool.    
 
Differentiation and polarization protocol of THP-1 cells 
 
For differentiation seed 1.3*10^6 cells in each well (MT6) with RPMI, 10% FBS (decomplemented), 1%Gln, 
0.3 µg/mL puromycin, 5 ng/ml PMA. Incubate for 48 h in humidified incubator (37°C, 5% CO2); During the 
process of differentiation verify the morphology of the cells. 
For polarization discard the medium, wash 3 times with PBS and add fresh medium (RPMI + 5 % FBS 
(decomplemented) + 1 % L- Gln + 0.3 µg/ml puromycin) with the polarizing stimuli:  
? M1 : 100 ng/mL LPS + 20 ng/mL INF gamma (2*10^5 IU/mg) 
? M2 : 20 ng/mL IL-4 (5*10^6 IU/mg) 
Incubate for 24 hours in humidified incubator (37°C, 5% CO2) then proceed with total RNA extraction 
(Qiagen). 
 
Quantitative real time PCR 
 
Total RNA was extracted was subjected to DNase treatment and was reverse transcribed with random 
hexamers using the High-capacity cDNA RT kit (Applied Biosystems). Primer sequences were designed 
with the Primer express program (Applied Biosystems). Real-time RT-PCR was performed on ABI PRISM 
7000 with the Power SYBR-green PCR Master Mix (Applied Biosystems), following the manufacturer's 
instructions. Amplification reactions were performed in triplicate. Following a polymerase activation step 
at 95°C for 10 minutes, samples were denatured at 95°C for 15'' and annealed/extended at 60°C for 1 
minute, for 40 cycles. Fluorescent signals generated during PCR amplification were monitored and 
analyzed with ABI PRISM 7000 SDS software (Applied Biosystems). The amount of target RNA, normalized 
to the endogenous reference gene, was calculated by means of log2 of expression level using 35 cycle as 
LOD. 
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RESULTS 
 
The experimental results produced during my PhD activities are as follows: 
 
Recombinant human RNASET2 protein purification 
 
Experimental evidence gathered in our group reported that the RNASET2 gene acts as a 
tumor antagonizing gene in an ovarian cancer model and that this role is not dependent on the catalytic 
activity of the protein [Acquati, 2005] [Acquati, 2011]. Moreover, our data strongly supported 
the hypothesis that RNASET2-mediated tumor suppression is carried out in the context of the cancer 
microenvironment. Indeed, the recruitment and activation of cells belonging to the monocyte-
macrophage lineage were shown to be crucial for the observed in vivo oncosuppressive role of RNASET2 
[Acquati, 2011] [Acquati, 2013]. 
 
In order to further investigate the mechanisms of RNASET2-mediated tumor suppression, the role of 
this protein in establishing a functional cross-talk between cancer cells and the tumor microenvironment 
must be thoroughly investigated. To shed light on these issues, the availability of highly pure recombinant 
RNASET2 protein is an essential requirement. 
 
To this purpose, we already had developed a protocols for expression and purification of recombinant 
RNASET2 protein in two different heterologous expression systems: the yeast Pichia pastoris and the 
baculovirus/insect cells system (BEVS) [Campomenosi, 2011]. In both systems, a catalytically competent 
RNASET2 protein was produced, with comparable levels of expression (about 30 mg of protein/l of 
conditioned medium). The P. pastoris system proved to be more advantageous, being more cost-effective 
with respect to BEVS and allowing an easier purification of the protein by affinity chromatography from a 
protein-free supernatant [Campomenosi, 2011]. However, a full exploitation of this research tool 
was precluded by several limitations inherent to both systems, such as: 
? protein heterogeneity (mostly in the BEVS derived material) due to high molecular weight 
species (mostly host cell proteins) co-eluting with the RNASET2 molecule; 
? a significant loss of the recombinant protein in both flow-through and wash fractions during 
affinity purification steps; 
? the presence of both mildly (38–45 kDa) and highly (50–80 kDa) glycosylated forms of the protein 
in the eluted fractions (mainly in RNASET2 preparations from P. pastoris); 
? the occurrence of endotoxin contamination, which precluded the use of the recombinant protein 
in functional assays to be carried out with cells from the monocyte/macrophage lineage, 
which likely represent the most relevant target of the RNASET2 protein in vivo. 
To overcome the listed limitations, we decided to focus our efforts on improving the Pichia pastoris system 
which was much easier to handle in our group in term of available facilities. 
 
The previous system used a strain of Pichia Pastoris (X33) transformed with a plasmid (pPICZ alpha A). The 
construct code for the human wild type protein RNASET2 tagged with tail of six His (6XHis tag) at the C-
terminus (wt_RNASET2-His) and the purification process rely only on an Ion Metal Affinity 
Chromatography (IMAC) step.  The main problems with this system is: 
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? A significant amount of protein (45%) is lost in the Flow Trough (FT) (tab1). 
? The eluate is contaminated with endotoxin.  
? The eluate in not homogenous and if it is treated with a polishing step (Size Exclusion 
Chromatography SEC) in order to remove the higher molecular weight, the recovery of protein 
drop to 26% of the input (fig 1) (tab1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 Comparison of IMAC, SEC, and negative-mode IEX for purification of 
the RNASET2 proteins from P. pastoris 
a Concentration of the RNASET2 proteins in conditioned media and IMAC 
eluates was determined by densitometric analysis of the corresponding 
immunoblots 
b Concentration of the RNASET2 proteins from SEC and IEX was determined 
by spectrophotometry  
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Our first attempt to improve the system was try different conditions in the purification protocol. In 
particular, we performed an IMAC without stringent washing steps (even avoiding more stringent washing 
steps we didn't manage to achieve a better recovery) follower by a negative Ion Exchange 
Chromatography (IEX) as a polishing step (fig 2). The IEX was a better solution rather than SEC in term of 
percentage of recovery (tab1) but still we were not satisfied by the loss in the FT (tab1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. SEC of wt_RNASET2-His from P. pastoris. Conditioned media from P. pastoris expressing 
wt_RNASET2-His were passed through Ni-NTA agarose columns manually equilibrated and eluted as 
described in Materials and Methods. Affinity isolated protein from P. pastoris was further separated on a 
Superdex 75 (10 x 300 mm) column using an ÄKTA Purifier FPLC system and chromatograms were recorded 
as UV absorbance at 280 nm (IMAC, dotted lines). wt_RNASET2-His containing fractions were pooled, 
concentrated and re-chromatographed on the same SEC column (IMAC/SEC, solid lines). IMAC- and 
IMAC/SEC- purified protein was run on 10% gels under denaturing and reducing conditions. Representative 
silver-stained gels are shown (1 mg of total proteins/lane). 
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Considering that most of the protein was lost in the FT and even "playing" with the binding condition 
didn't help in achieving a better performance, we decided to improve the system by adding another 6XHis 
tag to the N terminus of the protein (wt 2tag_RNASET2-His) (fig 3). 
We decided to keep the X33 as P. pastoris strain as host (X33 was already selected as a good strain for the 
production of RNASET2; considering the minor modification added by the new tag we decided not to 
explore the performances of other strains) and to clone the new construct (produced by PCR with ad hoc 
Figure 2. Negative-mode IEX of wt_RNASET2-His from P. pastoris. A) wt_RNASET2-His was isolated from P. 
pastoris conditioned medium by HisTrap HP (1 ml) columns and further purified on HiTrap Q XL (1 ml) columns 
by negative-mode anion exchange chromatography. A representative IEX chromatogram is shown where UV 
absorbance at 280 nm and mobile phase conductivity are reported as solid and dotted lines, respectively 
(upper panel). Unfractionated material (IMAC eluate), and HiTrap Q fractions (unbound, 37 mS/cm and 100% 
B) were analyzed on a Superdex 75 (10 x 300 mm) column. An overlay of the corresponding UV profiles at 280 
nm is shown (lower panel). B) The same fractions were run on 4-12% gradient gels under denaturing and 
reducing conditions. Proteins were revealed by either silver staining (upper panel) or western blotting (lower 
panel), using an anti-His monoclonal antibody (1 mg ad 200 ng of total proteins/lane, respectively). 
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primers) in the same pPICZ alpha A vector. After transformation, selection and screening we set up a small 
batch production and performed a comparative IMAC (fig 3) (for detail on cloning, transformation, 
selection and screening see Material and Methods). With this new system we managed to achieve a 
recovery of 95% of the input protein compared to the former 55% using the same IMAC protocol (tab 2). 
 
 
 
 
 
Figure 3. IMAC of wt_RNASET2-His and wt 2tag_RNASET2-His. A) Schematic representation of both single-
tagged and double-tagged wild-type RNASET2 protein sequences. In bold the 6xHis tag. CASI site is underlined; 
CASII site is in red. B) WB analysis with polyclonal anti-RNASET2 antibody. Both wt_RNASET2-His and wt 
2tag_RNASET2-His were purified from P. pastoris conditioned medium, using Ni-NTA agarose beads by gravity-
flow. Fractions collected from every step were loaded. The volume of sample loaded was normalized against 
the final volume of each fraction. C) Conditioned media from P. pastoris expressing either wt_RNASET2-His or 
wt 2tag_RNASET2-His were passed through a HisTrap HP (1 ml) column operated with an ÄKTA Purifier FPLC 
system. Recorded chromatograms are reported as dashed (1xHis-Tag) and solid (2xHis-Tag) lines, respectively. 
The dotted line indicates concentration of the eluent buffer (%B). Fractions eluted with 20, 40 and 250 mM 
imidazole were normalized by volume and run on 4-12% gradient gels under denaturing and reducing 
conditions. Representative silver-stained gels are shown in the inset. 
wt_RNASET2-His 
  
DKRLRDNHEWKKLIMVQHWPETVCEKIQNDCRDPPDYWTIHGLWPDKSEGCNRSWPFNLEEIKDLLPEMRAYWPDVIHSFPNRSRFWKHEWEKHGTCAAQVDALNSQKKYFGRSL
ELYRELDLNSVLLKLGIKPSINYYQVADFKDALARVYGVIPKIQCLPPSQDEEVQTIGQIELCLTKQDQQLQNCTEPGEQPSPKQEVWLANGAAESRGLRVCEDGPVFYPPPKKTKHYPYDV
PDYAHHHHHH 
  
wt 2tag_RNASET2-His 
  
EFHHHHHHDKRLRDNHEWKKLIMVQHWPETVCEKIQNDCRDPPDYWTIHGLWPDKSEGCNRSWPFNLEEIKDLLPEMRAYWPDVIHSFPNRSRFWKHEWEKHGTCAAQVDALNS
QKKYFGRSLELYRELDLNSVLLKLGIKPSINYYQVADFKDALARVYGVIPKIQCLPPSQDEEVQTIGQIELCLTKQDQQLQNCTEPGEQPSPKQEVWLANGAAESRGLRVCEDGPVFYPPPK
KTKHYPYDVPDYAHHHHHH 
A 
C B 
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The new developed system provides a significant increase in term of performance. Moreover, by placing 
the chromatography system under sterile condition, sanitizing all the lines and working with LPS tested 
buffers (or buffers cut with 10 kDa filters) throughout all the steps we managed to drop the LPS 
contamination of the purified protein to 0.003 EU/100 ug RNASET2 (0.3 pg LPS/ 100 ug RNASET2). 
Considering the use of metal chelating resins during the purification steps, we decided to test the end-
product protein preparation for contamination of Ni, Cd and Zn by Atomic Adsorption Spectroscopy (AAS). 
For all the metals the concentration was below the limit of detection of the instrument. 
The low endotoxin content and absence of contamination by metals are important features, 
especially considering the plan of studying the role of RNASET2 in macrophages polarization. 
 
Finally, the proper folding of the new recombinant human RNASET2 produced (wt 2tag_RNASET2-His) was 
checked by means of a zymogram (exploiting the ribonuclease activity of RNASET2) (fig 4). A 
catalytically inactive form of the protein (already developed in our laboratory) was used as negative 
control (H65/118F_RNASET2-His). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Comparison of IMAC purification of wt_RNASET2-His and wt 2tag_RNASET2-His from P. 
pastoris 
a Conditioned media (50 ml) were concentrated to a final volume of 9 ml (~5.6 fold) prior to IMAC. 
The values here reported refer to protein concentration in the non-concentrated media, as 
determined by densitometric analysis. 
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Analysis of the evolutionary conserved relationship between RNASET2 and immune cells 
 
T2 RNases represent one of the most widespread class of RNases, being found in viruses, bacteria, 
protozoans, plants and metazoans [Luhtala, 2010]. This feature, coupled to their rather unspecific 
substrate preference (they usually cleave RNAs at all four bases), suggest the occurrence of one or more 
ancient, evolutionarily relevant roles for T2 RNases. 
As already mentioned, several studies have reported the widespread tumor suppressive role for several 
members of the T2 RNase protein family and the recruitment of immune cells seems to be the one of the 
Figure 4. Zymographic analysis of the catalytic activity of wt 2tag_RNASET2-
His. Upper panel: zymography was performed using total RNA from Torula 
yeast as substrate. 600 ng of recombinant protein/lane were loaded. The 
activity of both wt 2tag_RNASET2-His protein was compared to that of the 
single-tagged wt RNASET2 protein (wt_RNASET2-His). The catalytically-
inactive mutant was loaded as negative control (H65/118F_RNASET2-His). 
Lower panel: the identity of the bands which showed ribonucleolytic activity 
was confirmed by immunodetection with polyclonal anti-RNASET2 antibody. 
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main causes of this suppression [Smirnoff, 2006; Schwartz, 2007; Acquati, 2011, 2013] nevertheless, we 
don't understand yet the mechanism behind this effect. 
In order to improve our knowledge of these functional features of T2 RNases and at the same time to 
evaluate their evolutionary conservation, we tested the role of human recombinant RNASET2 in the 
activation and recruitment of immune cells using as experimental model the Hirudo Verbana, a medicinal 
leech species closely related to Hirudo medicinalis. 
Hirudo is a consolidated experimental animal model for several reasons: 
? It represents a suitable tool for experimental manipulation, being cost-effective, easy to handle 
and devoid of significant ethical considerations in relation to its use and regulatory restrictions. 
? The main immune response processes in leeches have been shown to be strikingly similar to those 
reported in vertebrates, since they involve similar cellular mechanisms and a common equipment 
of key molecules playing pivotal roles for regulating hematopoietic cells activation and 
differentiation. 
? Any response evoked in leeches by a wide range of different stimuli is activated within a short 
period of time (6–24 h) and is clearly and easily detectable due to the small size and anatomical 
features of this experimental model [de Eguileor, 1999, 2003, 2004; Grimaldi, 2004, 2006; 
Tettamanti, 2004; Girardello, 2015a, b; Schorn, 2015b]. 
? The use of the biopolymer Matrigel (MG), once soaked with the molecule subject of the study, 
allows to investigate several key aspects of the immune response in leeches, making it possible to 
isolate and further characterize specific cell type [Grimaldi, 2008, 2009, 2011; Girardello, 2015a]. 
In order to evaluate the putative role of RNASET2 in the regulation of innate immune response in Hirudo, 
in particular in the activation and migration of macrophages, we first assessed the effects of recombinant 
human RNASET2 (rRNASET2) injection in the leech body wall. To this aim, morphological and 
immunohistochemical analyses were carried out on leech tissue sections from uninjured, PBS-injected, 
rRNASET2- injected (with or without preincubation of the recombinant protein with an anti-RNASET2 
antibody) and LPS-injected animals. The same analyses were also carried out on rRNASET2- soaked, 
polymerized matrigel pellets explanted from the leech body wall after implantation for 1 week. 
The body wall of unlesioned (fig 5 a) or PBS-injected (fig 5 b) leeches showed a typical cutaneous muscle 
sac, formed by epithelium and muscle fibers arranged in groups and surrounded by a loose connective 
tissue. In the body wall of these control animals, a few non-muscle cells were immersed in the connective 
tissue surrounding the muscles. By contrast, at 24 h (fig 5 c) and 1 week (fig 5 d, e) following rRNASET2 
injection, a large number of infiltrating cells was clearly detected underneath the epithelium and in the 
connective tissue surrounding the muscle fibers. A marked reorganization of the muscle layers in 
rRNASET2-treated animals was also evident at the injection site, since the distance between single muscle 
fields appeared to be greatly increased, due to the infiltration of several cells interposed between them. 
This cell infiltration process was closely associated with a massive reorganization of the connective tissue 
and the appearance of new blood vessels in the space between the muscle fields (fig 5 c–e). By contrast, 
in uninjured (fig 5 a) and PBS injected control leeches (fig 5 b) or in leeches injected with rRNASET2 
previously pre-incubated with the antiRNASET2 antibody (fig 5 f–h), muscle fields were in close reciprocal 
contact and both the infiltration of cells and the appearance of vessels between the groups of muscle 
fibers or underneath the epithelium were negligible (fig 5 f–h). 
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Figure 5. Light microscope morphological analysis of leech body wall sections. In unlesioned 
(a) and PBS-injected (b) animals, a few cells (arrowheads) among muscle fibers are visible; 24 
h (24h, c) and 1 week (1w d, e) following rRNASET2 injection, numerous migrating cells 
(arrowheads) and neovessels (arrows) are visible. Injection of rRNASET2 pre-incubated with 
the neutralizing anti-RNASET2 antibody (Ab) significantly reduces both cell migration and neo 
vessel formation (f–h). mu muscles; ep epithelium. Bars 100 μm. 
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Ultrastructural TEM analysis of unlesioned (fig 6 a) or PBS-injected (fig 6 b) leeches confirmed that muscle 
fibers forming the muscular fields were very close to each other and the extracellular matrix surrounding 
them was scant and devoid of cells. By contrast, 24 h (fig 6 c, d) and 1 week (fig 6 e, f) following rRNASET2 
injection, clearly recognizable neovessels were observed underneath the epithelium, with the vessels 
lumen containing circulating cells. The observed angiogenic process displayed the typical features of an 
inflammatory response-derived process [Grimaldi, 2006], with circulating cells extravasating and 
migrating into the nearby connective tissue and thereby differentiating into mature leukocytes, likely 
involved in the leech innate immune response. Indeed, a high prevalence of cells displaying the typical 
appearance of macrophages was detected in the extracellular matrix underlying the epithelium (fig 6 c) 
and surrounding the muscle fibers of rRNASET2-treated animals (fig 6 d, e). These cells were clearly 
distinguishable by an elongated shape, an irregular membrane (likely involved in the formation of 
pseudopodia, a typical feature of cells involved in active migration) (fig 6 e) and a cytoplasm with a large 
nucleus and a few electron-dense granules (fig 6 d). Besides the infiltration of immunocompetent cells, 
rRNASET2-treated leeches were also characterized by a massive fibroplasia across the entire body wall. 
As in vertebrates, leech fibroblasts are responsible for the synthesis and remodeling of the extracellular 
matrix [Tettamanti, 2005]. These cells were easily recognizable by TEM analysis in rRNASET2-injected 
animals due to their tapered shape and the presence of several lipid droplets in their 
cytoplasm. Moreover, the fibroblasts’ cell membrane was characterized by the presence of laminar 
projections, known to be involved in the formation of a cellular microenvironment that 
promotes fibrillogenesis (fig 6 f). As already observed by optical microscope analysis, the number of 
vessels and immunocompetent cells underneath the epithelium and between the groups of muscle fibers 
was very scant in animals injected with rRNASET2 that was pre-incubated with anti-rRNASET2 neutralizing 
antibody, (fig 6 g, h), suggesting that the observed tissue morphological changes represent a specific effect 
of rRNASET2 treatment. 
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In order to better define the cell types recruited in leech tissues following rRNASET2 injection and thus 
confirm the occurrence of a RNASET2-driven inflammatory response, immunofluorescence (IF) 
Figure 6. Ultrastructural analysis at TEM of leech body wall. details of a group 
of muscle fibers (mu) in unlesioned (a) and PBS-injected (b) leeches. Muscle 
fibers (mu) are close to each other and surrounded by scant extracellular 
matrix (ecm) devoid of cells. After 24 h from rRNASET2 injection (c, d), 
macrophages (arrows) and vessels (v) containing circulating cells (arrowheads) 
are visible underneath the epithelium. After 1 week from rRNASET2 injection, 
migrating macrophages (arrowhead in e) and fibroblasts (arrowhead in f) in 
active fibrillogenesis (arrows) are observable (e–f). The number of vessels and 
macrophages is highly reduced in rRNASET2 preincubated with anti-rRNASET2 
Ab injected leeches (g, h). Bars (a–c, e, g, h) 5 μm, (d, f) 2 μm. 
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experiments were performed on tissue cryosections from unlesioned, PBS-injected and 
rRNASET2- injected animals. Recombinant RNASET2-treated sections were investigated at both 24 h and 
1 week, with and without neutralizing anti-RNASET2 antibody pretreatment (figs 7 a– p; 8 a–d). 
Immunohistochemical assays were carried out with an anti-HmAIF-1 antibody, a known marker for leech 
macrophages [Drago, 2014; Schorn, 2015a, b] 
By these assays, HmAIF-1 turned out to be constitutively expressed at a low level in the body wall 
of uninjured animals. The protein was mainly detected in a few cells located in the connective tissue 
underlying the epithelium and surrounding the muscle fibers fields (fig 7 a, b). The same expression 
pattern was observed in the samples analyzed 24 h (fig 7 e, f) after PBS injection, suggesting that the 
mechanical stress induced by injection of a saline solution did not affect significantly the expression 
of HmAIF-1 in the leech body wall. 
By contrast, a highly increased number of HmAIF-1+ migrating cells were clearly recognizable 24 h (fig 7 i, 
j) and 1 week (fig 8 a) after rRNASET2 injection. These cells were mainly located under the epithelium 
and among muscle fibers. Strikingly, 24 h (fig 7 m, n) and 1 week (fig 8 c) from injection with rRNASET2 
pre-incubated with the neutralizing anti-RNASET2 antibody, the number of migrating HmAIF-1+ cells was 
significantly reduced. No signal was detected in the negative control experiments in which the primary 
antibodies were omitted (fig 7 d, h, l, p). 
Taken together, these data are indicative of a strong recruitment of cells belonging to the macrophage 
lineage at the rRNASET2 injection sites. 
Because no previous report of endogenous T2 ribonucleases in leeches are available, we decided to 
perform an IF with the antihuman RNASET2 antibody, over the same sections investigated for HmAIF-1. 
Interestingly, we observed a positive signal that seems to follow the same pattern of HmAIF-1, being 
constitutively expressed at low level in the untreated and PBS injected samples (fig 7 a, c, e, f) and 
overexpressed after rRNASET2 injection (fig 7 k, fig 8 b) but not if pre-incubated with the neutralizing anti-
RNASET2 antibody (fig 7 o; fig 8 d). 
This result suggest that the antihuman RNASET2 antibody might be able to detect a putative T2 
ribonuclease in leeches and this protein seems to follow the HmAIF-1 pattern of expression. 
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Figure 7. Immunofluorescence analysis of cryosections from medicinal leech body wall. 
unlesioned (a–c), PBS-injected (e–g), rRNASET2-injected (i–k) and neutralizing antibody 
preincubated rRNASET2-injected animals (m–o). The anti-HmAIF-1 and anti-RNASET2 antibodies 
stain in red a few cells among muscle fibers (mu) and underneath the epithelium (ep) in unlesioned, 
PBS-injected and antiRNASET2-neutralized, rRNASET2 injected leeches, whereas several migrating 
immune-responsive cells located under the epithelium (ep) and among muscles (mu) are detected 
24 h following RNASET2 injection. No signal is detected in negative control experiments in which 
the primary antibodies were omitted (d, h, l, p). Cell nuclei stained blue by treatment with DAPI. 
Bars 100 μm  
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To further confirm the ability of rRNASET2 to induce macrophages migration in vivo, recombinant 
RNASET2 protein was added to MG biopolymer held at a liquid state and the mixture was subsequently 
inoculated in leeches; the polymer once injected become a sponge that release rRNASET2 and capture 
recruited cells. This approach provides a better understanding of the effect of rRNASET2 by reducing the 
complexity of the sample under study (a slice of MG instead of a slice of leech) still maintaining the the 
salient characteristics of an in vivo system. 
In order to characterize the cell types infiltrating the polymerized biopolymer, MG solid pellets formed 
following inoculation were explanted after 1 week and processed for standard histological and 
immunofluorescence analyses using anti-CD68, anti-HmAIF-1 (both specific for leech macrophages) 
[Schorn, 2015a, b] and anti-RNASET2 antibodies (fig 9 a–o). In keeping with our previous results, MG 
samples containing rRNASET2 protein appeared massively infiltrated by elongated and irregularly-shaped 
cells characterized by numerous cytoplasmic expansions (fig 9 g). These cells were HmAIF-1+ (fig 9 h), 
CD68+(fig 9 j) and RNASET2+(fig 9 k). A much lower number of infiltrating cells was observed in control 
MG specimens lacking rRNASET2 (fig 9 a, b), or added with PBS (fig 9 d, e) or rRNASET2 pre-incubated with 
anti-RNASET2 antibody (fig 9 m, n). No signal was detected in negative control experiments in which the 
primary antibodies were omitted (fig 9 c, f, i, l, o). 
 
  
 
 
 
 
 
 
 
 
Figure 8. Ultrastructural analysis at TEM of leech body wall. 
injected with rRNASET2 (a, b) or rRNASET2 pre-incubated with 
the neutralizing anti-RNASET2 antibody (c, d). One week 
following injection of RNASET2 alone, several HmAIF-1+ and 
anti RNASET2+ cells (in red) are mainly located underneath 
the epithelium (ep). Cell nuclei are stained in blue with DAPI. 
Bars 50 μm. 
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Figure 9. Morphological and immunohistochemical analyses of MG sponges. untreated control MG sponges 
(a–c) and MG sponges treated with PBS (d–f), rRNASET2 (g–l) and neutralizing antibody-pretreated rRNASET2 
(m–o). After 1 week, only MG plugs supplemented with rRNASET2 are highly infiltrated by elongated and 
irregularly shaped characterized cells and by numerous cytoplasmic expansions (g). These cells are HmAIF- 1+ 
(h), CD68+ (j) and RNASET2+ (k). Cell nuclei are stained in blue with DAPI (h, i). No signal is detected in negative 
control experiments in which the primary antibodies are omitted (c, f, i, l, o). Bars (a–i, m–o) 100 μm, (j–l) 10 
μm. 
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We next addressed the putative involvement of rRNASET2 in regulating the inflammatory response 
following injection with LPS, a well-known strong stimulator of innate immune response in almost all 
eukaryotic species, ranging from insects to humans. It was already reported that LPS injection promotes 
a massive migration of macrophages in the body wall of Hirudo [de Eguileor, 1999; Schorn, 2015a]. 
The immunophenotype of cells involved in LPS-mediated inflammatory response was evaluated by 
double-labeling with an anti-RNASET2 antibody and anti-HmAIF-1 or anti-CD68 antibodies. 
As expected, the assays showed that, unlike unlesioned animals (fig 10 a, b), LPS-injected animals (fig 10 
c, d) displayed a marked migration of macrophages that were mainly localized underneath the epithelium 
and in the connective tissue surrounding the muscle fibers. Strikingly, these infiltrating macrophages were 
expressing both RNASET2 and CD68. Thus, the massive recruitment of macrophages coupled to 
upregulation of endogenous RNASET2 that we previously observed following rRNASET2 treatment was 
recapitulated when leeches were challenged with a strong inflammatory stimulus. Moreover, the cellular 
source of leech endogenous RNASET2 turned out to be the macrophage cell itself. 
To confirm the result observed by IF, the RNASET2 and HmAIF-1 expression pattern of uninjured, PBS-
treated, rRNASET2-treated (with and without pre-incubation with the neutralizing antiRNASET2 antibody) 
and LPS-challenged animals was also evaluated by means of western blot analysis (fig 10 e, f). The injection 
of the anti-RNASET2 antibody alone was also performed as a further control. The analysis was carried out 
on protein extracts taken from the leech body wall at the site of injection. 
Two main RNASET2-immunoreactive bands of approximately 34 and 29 kDa (the latter being visible only 
in a subset of the tested samples) were detected in leech tissues (fig 10 e). Of note, a control sample from 
the human OVCAR3 ovarian cancer cell line (known to express high endogenous RNASET2 levels) also 
showed two main antiRNASET2-reactive bands, although their molecular masses were slightly different 
from those observed in leech tissues (we do not have any information on the endogenous leech protein 
hence the difference in term of migration might be due to differences in term of sequence or post-
translational modifications). 
By using an anti-AIF-1 antibody, a single band of 18 kDa corresponding to the expected molecular weight 
for HmAIF-1 [Schorn, 2015a] was detected (fig 10 f). Strikingly, the expression pattern of RNASET2 and 
AIF-1 turned out to be remarkably similar in most if not all the samples tested and was in keeping with 
the pattern previously reported by immunofluorescence assays. Indeed, both RNASET2 and HmAIF-1 
turned out to be constitutively expressed at a low baseline level in unlesioned, PBS and rRNASET2 plus 
neutralizing anti-RNASET2 antibody injected animals (fig 10 e, f). In contrast, expression of both RNASET2 
and HmAIF-1 was significantly increased in the samples from LPS and RNASET2-injected 
animals. Moreover, a very weak or undetectable signal was observed in the proteins extract of leech 
injected with the antiRNASET2 antibody alone (fig 10 e, f), again suggesting the occurrence of a RNASET2-
specific effect. Thus, rRNASET2 injection was shown to induce a change in the expression pattern of both 
proteins that is very similar to that induced by injection with a highly pro-inflammatory agent such as LPS. 
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Figure 10. Co-immunolocalization and WB analysis. Double immunolocalization of RNASET2 and HmAIF-1 or RNASET2 
and CD68 of unlesioned (a, b), LPS-injected (c, d) leech body wall and western blot analysis (e, f). At 24 h following LPS 
injection, numerous RNASET2+/HmAIF-1+ and RNASET2+/CD68+ macrophages (yellow) migrating towards the injected 
area are visible under the epithelium (ep) and among the muscle fibers (mu). Double immunostaining is performed 
with anti-RNASET2 (red) and anti HmAIF-1 or anti-CD68 (green). No signal is detected in negative control experiments 
in which primary antibodies are omitted. Nuclei are stained in blue with DAPI. Bars (a–d) 50 μm. e, f Western blot 
analysis. A protein extract of human OVCAR3 ovarian cancer cell line (H), used as positive control and of body wall 
biopsies at the injection sites from unlesioned (U), PBS-treated, anti-RNASET2 alone-treated (Ab), rRNASET2-treated 
(RN), rRNASET2 plus neutralizing anti-RNASET2 antibody (RN+Ab) or LPS-treated leeches were probed with the 
antiRNASET2 (e) or anti-HmAIF-1 (f) antibodies. The antibody antiRNASET2 recognizes two RNASET2-immunoreactive 
bands of approximately 34 and 29 kDa in leech tissues and of 36 and 27 kDa in OVCAR3 cell line exctract, while the 
anti-HmAIF-1 detects in leech tissues a specific immunoreactive band of about 18 kDa, according to the molecular 
weight ladder (kDa). The housekeeping protein Dglyceraldehyde-3-phosphate dehydrogenase (GAPDH) is used as a 
loading control. No signal was observed in the proteins extract of leech injected with the Ab alone. 
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Attempts to identify a putative receptor for RNASET2 
 
Recent experiments carried out in our group demonstrated that RNASET2 is actively internalized by a 
human cancer cell line [Lualdi, 2015], this finding coupled with the evidence gathered from chemotaxis 
experiments [Acquati, 2013], allowed us to hypothesized that there could be a membrane-bound 
interactor for this protein. Therefore, in order to get a better insight of this molecular mechanism we tried 
several strategies to identify a putative receptor for RNASET2. 
The basic idea behind all of our approaches was to try to covalently link RNASET2 (either the endogenous 
protein or the human recombinant protein) to any interactor and, after purification of the complex, 
perform a MS analysis to characterize the interactants. 
It is important to specify that before proceeding to the purification step we needed to set up an 
experimental system (composed of a cell line and an assay) which is able to produce a detectable complex. 
In this sense, the crosslinking should change the apparent molecular weight of the linked interactor, 
therefore we planned to identify the formation of a complex by monitoring the shift in molecular weight 
of RNASET2 positive signals by WB. 
 
As the first approach we performed a chemical modification of the purified protein. The modification was 
made with different NHS-ester diazirines (SDA, LC-SDA, Sulfo-SDA and Sulfo-LC-SDA). These compound 
are heterobifunctional crosslinkers that contain an amine-reactive N-hydroxysuccinimide (NHS) ester and 
a photoactivatable diazirine ring. NHS esters react efficiently with primary amino groups in pH 7-9 buffers 
to form stable amide bonds; the product is a photoactivable protein probe. Exposure of diazirines to long-
wave UV light creates reactive carbene intermediates that can form covalent bonds through addition 
reactions with any amino acid side chain or peptide backbone within the spacer arm distance (1.25 nm 
for LC-compound and 0.39 nm for non LC-compound). 
The modified protein was added to OVCAR3 silenced cells (among a panel of cell lines the latter resulted 
to be the strongest binder for RNASET2 [unpublished data]; the silenced model ensures that the putative 
receptor, if present, is not already bound to the endogenous protein) and irradiated with UV light. The 
protein extract was analyzed by WB but despite several attempt, we could not observe any shift in the 
molecular weight of RNASET2. 
 
As the second approach we decided to perform metabolic labeling of OVCAR3 cells using two chemical L-
Photo-Leucine (Photo-L) and L-Photo-Methionine (Photo-M). 
Photo-L and Photo-M are amino acid derivatives that contain diazirine rings for UV photocrosslinking of 
proteins. These photo-active amino acids substitute for their respective natural amino acids and are 
incorporated directly into proteins using the endogenous mammalian translation machinery. The overall 
incorporation rate depends on amino acid frequency, sequence length, protein abundance and protein 
turnover. Photoactivation of the diazirine rings creates reactive carbene intermediates that irreversibly 
crosslink proteins generally within protein-protein interaction domains.  
In this case we exploited the high RNASET2 endogenous expression of OVCAR3 cell line grown with Photo-
L and Photo-M before irradiation and analysis of the protein extract. After several attempt, even exploring 
different conditions, we didn't manage to observe any shift in the molecular weight of RNASET2, meaning 
we were not able to produce any detectable complex. 
 
Considering that most of the result obtained show evidence of an interaction between RNASET2 and cells 
belonging to the monocyte/macrophage lineage, we decided to test the system with a promyelocytic cell 
line. 
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In our last attempt we incubated the recombinant human RNASET2 with U937 cell line (a promyelocytic 
cell line which do not show any detectable expression of endogenous RNASET2) and in order to stabilize 
the putative complex we used a non UV activable crosslinker (BS3). 
BS3 ((bis[sulfosuccinimidyl] suberate) is a water soluble homobifunctional N-hydroxysuccinimide ester 
(NHS ester), it reacts efficiently with primary amino groups in pH 7 to 9 buffers to form stable amide 
bonds. The reaction generally involves the side chain of lysine residues and the N-terminus of each 
polypeptide. As the chemical crosslinkers presented before, BS3 is able to covalently link two or more 
proteins in close proximity, but in this case there is no need to activate the reaction with UV irradiation. 
With this experimental setup we finally managed to see a shift in the molecular weight of RNASET2 by WB 
(fig 11 a), but unfortunately, despite several attempts, once we moved to the purification step we didn't 
manage to elute any complex (Fig 11 b). 
 
 
 
 
 
a b 
Figure 11. WB analysis for the identification of the putative RNASET2 receptor (anti-human RNASET2): 
a) The U937 cell line do non express detectable level of endogenous RNASET2 (U937 -/-) and after addition 
of the crosslinker do not show any artefact (U937 -/BS3). The addition of rRNASET2 to the cells remains 
unexpectedly clearly visible in the cellular extract (U937 RNASET2/-). If we apply the crosslinker to the latter 
condition, we manage to see a shift at higher molecular weight for RNASET2 positive signals (U937 
RNASET2/BS3). b) Purification of the extract over NHS-agarose beads functionalized with the anti-human 
RNASET2 antibody. In the elution step we cannot see any positive signal at higher molecular weight, with a 
limit of detection of 3ng of protein. 
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Development of an assay to study the role of RNASET2 in macrophages polarization 
 
The experimental overexpression of RNASET2 in tumor xenografts has been associated with their 
suppression in two complementary in vivo systems [Acquati, 2011, 2013]. As previously mentioned the 
observed suppression seems to be due to the recruitment of host immune cells belonging to the 
monocyte/macrophages lineage; further analysis identified the infiltrate as M1 polarized macrophages 
[Acquati, 2013]. 
The role of different tumor-infiltrating macrophage types is still debated but most of the time they are 
associated with a faster spreading of the disease and in general with a worst outcome.  
Several experiments have demonstrated that macrophages have the potential to kill tumor cells in vitro 
when appropriately stimulated, however, bacterial stimuli and Th1 cytokines inducing M1 type 
polarization are usually not present at the tumor site. Here, in contrast, differentiating macrophages are 
likely to encounter factors that most frequently polarize them toward the M2 phenotype, which therefore 
are more likely to be involved in the process of tumor progression and invasion [Mantovani, 2002]. 
Considering the evidence gathered so far we proposed that RNASET2 might have a role in the polarization 
of macrophages, hence the last part of the project was dedicated to the development of a proper assay 
to test the potential of RNASET2 in driving macrophages polarization. As mentioned before, tumors 
generally provide factors stimulating the alternative activation of macrophages towards the M2 type, 
therefore, along assessing whether RNASET2 is able to drive naive macrophages polarization, we were 
also interested in assessing a potential interference role in already polarized macrophages. 
In short we planned to develop an efficient and reliable system of production and detection of M0, M1 
and M2 macrophages removing any bias from endogenous RNASET2 expression. 
 
In order to reduce the variability among human donor subjects we decided to focus our efforts on the 
development of an assay based on a cell line. Considering the consistent literature available, our first 
choice was the promyelocytic cell line THP1, which was already reported as a model for differentiation 
and polarization studies. 
Considering our final aim (namely the study of the effect of RNASET2 in macrophages polarization) we 
needed to quantify the endogenous expression of RNASET2 in the THP1 cell line, which could be a 
disturbing variable. Indeed, the expression of the endogenous protein is quite consistent hence our first 
step was the development of a silenced pool of THP1 cells. 
We designed a short interfering RNA (siRNA) based on the sequence of the human RNASET2 protein and 
cloned it in a pSico vector; the whole construct was nucleofected and, after selection, the expression of 
the pool was tested by WB analysis (for detail see Material and Methods). The new pool of THP1 cells 
have been effectively silenced for RNASET2 expression (fig 12). 
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The M1/M2 polarization is a feature macrophage-specific and the THP-1 cells, being of a promyelocytic 
origin, are closer to the monocyte cells; thus, as soon as we managed to obtain the silenced pool of cells, 
we moved to the development of a proper differentiation protocol. 
To achieve this goal, we looked up the literature and identified some important guidelines: The most 
common approach to obtain differentiated macrophages from THP-1 cells is the use of phorbol 12-
myristate 13-acetate (PMA) [Daigneault, 2010]. Generally, it is reported that the suggested working 
concentration to obtain macrophages from THP-1 cells is 100 ng/ml, however, some papers [Park, 2007; 
Maeß, 2014], suggest that this concentration might be high enough to upregulate the expressions of some 
genes in differentiated macrophages, which in turn could overshadow the increase in gene expression 
induced by other stimuli. Therefore, we decided to lower the PMA concentration to 5 ng/ml. 
After some attempts, changing concentration of PMA and length of the treatment, we managed to obtain 
fully differentiated macrophages (M0) from silenced THP-1 cells applying 5 ng/ml PMA for 48h (fig 13).  
To assess the effective differentiation, we relied on morphological observations (fig 13 a) (macrophages 
are attached cells, instead monocytes are floating cells) and additionally we tested the expression of a 
known marker of differentiation (CD68) [Genin, 2015] by qPCR (fig 13 b). 
 
 
 
 
 
Figure 12. WB analysis of the expression of RNASET2 in THP-1 
cells before and after silencing: 
The upper panel show the level of expression of the endogenous 
RNASET2 in THP-1 cells before silencing (control) and after 
selection of the pool of silenced cells (silenced). As normalizer 
we show the expression of Tubulin. 
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20X 
THP-1 DMSO 48h 
THP-1 PMA 5 ng/ml 48h 
Figure 13. differentiation of silenced THP-1 cells into macrophages: 
After treatment of the silenced pool of THP-1 cells with PMA 5 ng/ml for 48h the cells are clearly attached to 
the petri dish ((a) lower panel). To assess that the differentiation is unequivocally due to the effect of PMA, as 
control, we treated the cells with the vehicle of PMA (DMSO); in this case the cells do not assumed the typical 
flat shape and remains floating ((a) upper panel). 
(b) To further confirm the effectiveness of the differentiation protocol we also tested by qPCR the expression 
of a well-known marker (CD68). Here is presented a strip plot showing data gathered from three independent 
experiments. The expression is reported as log2 of the expression level (LOD 35 cycles), using as normalizer 
the expression of GAPDH. The difference observed is significant with a p-value < 0.05 (t.test) and an effect size 
of 6.90 (Cohen’s d). 
a b 
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The final step in the development of our functional assay entailed the setting up of a protocol for defining 
a proper transcriptional profile (M1 and M2). 
As mentioned before the M1-M2 definition is an important issue that has to be taken into account 
experimentally. This basic definition actually considers different activation scenarios (different mediators 
can be used to produce "polarized macrophages"):  the M1 type is normally produced from exposure of 
M0 macrophages to INF-gamma and LPS whereas the M2 is produced from exposure of M0 macrophages 
to IL-4.  These are just two prototypic cases of a spectrum of possible profiles that cannot be easily binned 
into defined groups [Stout, 2004; Mantovani, 2005; Edwards, 2006; Biswas, 2010; Martinez, 2014]. 
To avoid misunderstanding, the recommendation is to adopt a nomenclature linked to the activation 
standards, i.e., M (IFN-g + LPS) and M(IL-4) instead of M1 and M2 [Murray, 2014]. 
In our case we decided to focus our efforts on developing a protocol to obtain the two more classical 
activation profiles, M (IFN-g + LPS) and M(IL-4) hence, for simplicity, from now on we will keep using the 
M1 and M2 definition referring to M (IFN-g + LPS) and M(IL-4) macrophages. 
 
To obtain M1 macrophages we exposed M0 macrophages for 24h to 100 ng/ml of LPS and 20 ng/ml of 
INF-g and to obtain M2 macrophages 24h to 20 ng/ml of IL-4 (for detail see Material and 
Methods). Following this protocol, we managed to obtain differentiated macrophages (M1 and M2) 
without exploring other solutions (fig 14). 
 
The association of a sample to a specific polarization profile (M1 or M2) cannot rely on a single marker 
therefore, we chose a small panel of known marker of polarization tested by qPCR (fig 14 a). 
TNF, CXCL10, CCL19 are reported as marker of M1 polarization, meaning that the expression of those 
genes is expected to be higher in M1 compared to M2 [Maeß, 2014]. 
CCL22, MRC1, MSR1 are reported as marker of M2 polarization, meaning that the expression of those 
genes is expected to be higher in M2 compared to M1 [Martinez, 2006; Medina, 2011]. It is clearly visible 
that all the genes listed above behaved as expected (fig 14 a). 
 
Considering the final step of the assay (namely to assess whether RNASET2 is able to drive/interfere with 
macrophages polarization), as the last control, we decided to check whether our macrophage samples 
were able to "transit" form their assigned profile. In other terms we wanted to develop a control that 
could tell us whether the macrophages still retained the plasticity to change their profile according to 
external stimuli.    
Definitely the M0 macrophages produced were as expected, in fact, when exposed to known polarizing 
stimuli, they assumed the expected polarization profile (fig 14 a, b). The next main question concerned 
M1 and M2 macrophages; were our M1cells still able to change their profile if exposed to known M2 
stimuli and what about the M2 cells exposed to known M1? 
To answer this question, we decided to use as a control M0 cells exposed to both the M1 and M2 stimuli 
(these samples were called MX). The result (fig 14 a, b) showed that the profile obtained was neither M1 
nor M2, suggesting that the cells prepared with our system still retained the characteristic/desired 
plasticity to properly respond to external signals. 
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Considering all the data gathered so far we think that this system might be used as an assay to assess the 
role of RNASET2 (or any other compound) in macrophages polarization. 
M1 markers M2 markers 
a b 
c 
Figure 14. analysis of the expression of known marker of polarization: 
We tested the expression of known marker of polarization over the end-product of our 
polarization protocol. In the strip plot (a) is shown, as expected, that each cell types (M1 vs. 
M2) correctly overexpress the specific markers.  
MX is a control sample derived from the exposure of M0 to M1 and M2 stimuli; the purpose 
of this control is to verify whether either M1 or M2 induced macrophages (produced with our 
system) are still able to react to contradictory stimuli. As clearly shown in the heatmap (b) MX 
are not associable to any phenotype, meaning that both M1 and M2 induced profile can be 
still influenced by external stimuli.  
Finally, the PCA (c) recapitulate both the strip plot and the heatmap. Each sample is clearly 
separated from the others; the system developed might be ready to test the role of RNASET2 
(or any other compound) in macrophages polarization.  
In (a) are shown data gathered from four independent experiments. The expression is reported 
as log2 of the expression level (LOD 35 cycles), using as normalizer the expression of GAPDH. 
The difference observed between the expression level in M1 and M2 is significant with a p-
value < 0.05 for all the markers (MANOVA followed by ANOVA over every variable and 
TukeyHSD test) the effect size estimated is grater that 0.9 for each variable (Ƞ^2). 
To produce (b) expression data were further normalized by standardization (z-scores). 
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DISCUSSION 
 
The RNASET2 gene encodes for the only human secreted acid ribonuclease of the T2 family. This gene 
maps in 6q27, a region that is consistently found rearranged in many solid and hematological tumors 
[Acquati, 2005]. Experimental data gathered in our laboratory have demonstrated the role of RNASET2 as 
a tumor suppressor gene which is endowed with several functions including chemotactic and possibly 
activating activities toward the monocyte/macrophage population [Acquati, 2011]. In a mouse xenograft 
model, we have recently reported that inoculation of human ovarian cancer-derived cells forced to 
overexpress RNASET2 led to the development of small, growth-suppressed tumors, characterized by a 
strong infiltrate of host-derived innate immunity cells, which have been identified as mainly M1 polarized 
macrophages. By contrast, control cells not expressing RNASET2, developed large, fast-growing tumors 
with no sign of macrophage infiltration. 
Further investigations proved that recombinant RNASET2 (produced in either baculovirus or Pichia 
pastoris expression system) displayed a marked chemotactic activity in vitro, most likely dependent on a 
subfamily of G-protein Coupled Receptors associated with inhibitory G protein [Acquati, 2013]. 
Taken together, these results led us to suggest that RNASET2-mediated in vivo tumor suppression is a non-
cell-autonomous process which result in the recruitment of macrophages into the tumor mass. 
Based on such evidences, we decided to further investigate the relation between RNASET2 and cells 
belonging to the monocyte-macrophages lineage. 
 
Most of the experiments we planned to carry out involved the use of purified recombinant human 
RNASET2, hence, the first step of the project was the development of a reliable supply system. 
Two different sources of production and purification of human RNASET2 protein were already available 
in our lab (P. pastoris and BEVS) [Campomenosi, 2011], however, a full exploitation of these reagents 
was precluded by several limitations inherent to both systems. The end-
product was highly heterogeneous due to high molecular weight species co-eluting with the 
RNASET2 molecule. Moreover, the purification steps were not optimized and a significant amount of 
recombinant protein was lost in the in both flow-through and wash fractions during affinity purification. 
Finally, the eluted protein displayed a significant LPS contamination, which clearly precluded its use in 
functional assays involving cells from the monocyte/macrophage lineage that likely represent the most 
relevant target of the RNASET2 protein in vivo. 
To overcome these limitation, we decided to focus our efforts on improving the P. pastoris expression 
system, which was more cost-effective and easier to handle in term of available facilities. 
The previously described system [Campomenosi, 2011] made use of the X33 Pichia Pastoris strain, 
transformed with a plasmid (pPICZ alpha A) coding for the human wild type RNASET2 protein tagged with 
a C-terminal 6XHis tag (wt_RNASET2-His). The purification process relied on an IMAC followed by a SEC as 
polishing step. 
Our first attempt to improve the system was to explore new purification conditions. By this approach, we 
manage to assess that the polishing step with SEC should be replaced with an IEX, but still a considerable 
amount of protein was lost in the FT. To solve the problem, we added another 6XHis tag to the construct 
coding for the human RNASET2 and managed to significantly improve the recovery of the input protein. 
Finally, we confirmed the successful yield increase of the new recombinant protein by performing a 
zymogram. 
Considering the downstream applications of the purified human RNASET2, contamination of the 
preparation by metals (especially Ni, Cd, Zn) and endotoxin are important factor to control in order to 
properly assess a relationship between a specific treatment (in our case the addition of recombinant 
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human RNASET2) and immune cell response. Applying the proper care in the preparation of the buffers 
and the handling of the sample we manage to achieve a low endotoxin content and an undetectable level 
of contamination by metals (Ni, Cd, Zn). 
 
P. pastoris provide all the features of eukaryotic protein synthesis, making it a better expression 
system compared to bacteria as host for recombinant eukaryotic proteins. The recombinant human 
RNASET2 produced with this new system thus meets the minimum requirements to perform reliable 
studies with human macrophages. However, despite having the same sequence of the human protein, the 
recombinant RNASET2 expressed in this system is slightly different from the RNASET2 produced by human 
protein produced by human cells, and a main concern is represented by the pattern of protein 
glycosylation. Saccharomyces cerevisiae (another widely used host for recombinant protein production) 
and Pichia pastoris mainly display N-linked glycosylation of the high-mannose type, but the length of the 
oligosaccharide chains post-translationally added to Pichia proteins (average 8–14 mannose residues per 
side chain) is much shorter than the one observed in Saccharomyces cerevisiae (50– 150 mannose 
residues) [Grinna, 1989; Tschopp, 1987b], whose proteins are known to be particularly unsuitable for 
therapeutic use due to the strong antigenic response. In this context, the Pichia pastoris glycosylation 
pattern more closely resembles the pattern observed in higher eukaryotes [Cregg, 1993]. 
From these premises and as a possible future research option, we evaluated two ways to further improve 
the experimental system. 
The first idea is to replace P. pastoris with a human cell line in order to produce a “fully human” 
protein. We carried out a pilot experiment in the Hey3Met2 cell line (a clone derived from the ovarian 
carcinoma cell line HEY4) but we could not achieve adequate level of expression. A future option could be 
to turn to the PER-C6 cell line (from human retinal tissue), that has been reported to reach 500 mg/l of 
recombinant proteins [Jones, 2003]. 
An alternative approach is to perform a native deglycosylation of the batch of protein currently available. 
As a pilot experiment we tested different enzymes and identified Endoglycosidase H (EndoH) as a good 
candidate. EndoH is a recombinant glycosidase which cleaves within the chitobiose core of high mannose 
and some hybrid oligosaccharides from N-linked glycoproteins [Koide, 1974] Since it does not need access 
to the protein backbone to exploit its activity, it represents a suitable enzyme for native deglycosylation 
assays. We are currently planning to perform a Mass Spectrometry (MS) analysis of the end-product from 
EndoH digestion of recombinant RNASET2 to assess the level of deglycosylation reached with our protocol. 
The native deglycosylation might be useful not only as an alternative to the PER-C6 approach, but could 
also be applied to the “fully human” protein to further investigate the role of glycosylation in monocyte 
recruitment and macrophages polarization. 
 
As previously mentioned, several studies have reported the consistent tumor suppressive role for several 
members of the T2 RNase protein family [Smirnoff, 2006; Schwartz, 2007] and the recruitment of immune 
cells seems to be involved in this suppression [Acquati, 2011, 2013]. 
In order to improve our knowledge of these functional features of T2 RNases and at the same time to 
evaluate their evolutionary conservation, we tested the role of human recombinant RNASET2 in the 
activation and recruitment of immune cells by injecting recombinant human RNASET2 in the body wall of 
Hirudo verbena a useful model system for our purposes. 
 
After rRNASET2 injection, a significant increase in the production of collagen fibrils and a consequent 
remodeling of the muscle layers was observed. The resulting massive production of connective tissues is 
then used as a scaffold for immune cells migration and for proper orientation of growth of new vessels 
[de Eguileor, 2004; Tettamanti, 2004]. In this regard, it is worth noting that human RNASET2 was recently 
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shown to affect both the cytoskeletal organization and the migratory pattern of ovarian cancer cell lines 
[Lualdi, 2015]. 
 
Injection of human recombinant RNASET2 was also shown to induce a massive migration of cells belonging 
to the macrophages lineage (characterized as HmAIF-1+ and CD68+ cells) within 24 h, coupled to the 
formation of new blood vessels. 
The observed inflammatory response was specifically dependent of recombinant RNASET2 injection, since 
infiltrating macrophages and neo-vessel formation were not observed following injection of either PBS or 
rRNASET2 protein that was pre-incubated with a neutralizing anti-RNASET2 antibody. 
Taken together, these data strongly suggest that rRNASET2 injection in leeches induces a 
marked inflammatory response characterized by macrophage recruitment. 
  
Unexpectedly we observed a positive signal both by IF and western blot using the anti-human RNASET2 
antibody with leech cells. This result led us to suppose the existence of a putative endogenous and 
homologous T2 ribonuclease(s) in Hirudo. 
In this regard, the observation that recombinant RNASET2-mediated infiltration of leech macrophages is 
associated with a marked increase in the expression of putative endogenous RNASET2 by the same 
macrophage cells suggests that such an endogenous RNASET2 increase might further contribute in the 
recruitment and accumulation of more macrophages in the stimulated body region. Although the 
occurrence of such RNASET2-based positive feedback mechanisms on target infiltrating cells could be 
speculative, our results though are in agreement with data previously reported in other organisms. 
Indeed, proteins belonging to the Rh/T2/S ribonuclease family (including RNASE T2) are known to be 
actively secreted from cells belonging to different phyla ranging from yeast to human and once in the 
extracellular medium they exert their actions [Luhtala, 2010; Acquati, 2011, 2013].  
 
Taken together, these observations are in keeping with the role of RNASET2 as an inducer of a consistent 
inflammatory response.  Of note, RNASET2-mediated activation and recruitment of macrophages seems 
to represent an evolutionarily conserved process, since in this work we were able to recapitulate it also in 
an invertebrate experimental model. In keeping with this hypothesis, recent work on the trematode 
Schistosoma mansoni has demonstrated a role for a T2 RNase protein encoded by the parasite’s genome 
(omega-1) in the modulation of the innate immune response in infected hosts [Ferguson, 2015].  
We investigated the marked RNASET2-mediated infiltration of leech macrophages observed in vivo by 
further assessing the chemotactic activity of recombinant RNASET2, using a consolidated experimental 
approach based on injection of MG biopolymers supplemented with soluble factors in the leech body wall. 
Histological and immunocytochemical assays on explanted rRNASET2- supplemented MG pellets showed 
a massive infiltration of host cells that stained positive for CD68 or HmAIF-1 markers, thus providing 
further evidence in support of the chemotactic activity of RNASET2 on macrophage cells. 
 
Finally, we show that injection of LPS in the body wall of leech not only causes a massive migration of 
CD68+/ HmAIF-1+macrophages as previously described [de Eguileor, 1999; Schorn, 2015a,b] but also 
induces a strongly increased expression of endogenous RNASET2 in these migrating macrophages, as 
assessed by both immunohistochemical and western blot analysis. It is well known that, in response to 
infections, leech macrophages produce antimicrobial proteins and peptides that specifically disrupt 
several components of Gram-positive bacterial cell walls [Schikorski, 2008; Hildebrandt, 2011]. The 
observed increase of homologous RNASET2 expression by leech macrophages could therefore be directly 
correlated to its putative ability to act as a stress response protein by priming host macrophages for 
mounting an anti-bacterial response. In this regard, it is worth noting that a marked stress response role 
for human RNASET2 has also been recently reported in human cancer cells [Lualdi, 2015], 
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again supporting the occurrence of an ancient and evolutionarily conserved role for this gene. Moreover, 
since some ribonucleases have been described to display a marked antimicrobial activity [Boix, 2012], a 
direct anti-bacterial role for the RNASET2 enzyme cannot be ruled out, although this hypothesis remains 
largely speculative at present. 
Thus the data reported provide compelling evidence in support of a role for RNASET2 as a key component 
of the innate immune system, not only in vertebrates but also in invertebrates. If confirmed by further 
investigations, this scenario would suggest a complex, pleiotropic role for RNASET2 in orchestrating an 
evolutionarily conserved inflammatory response, mainly based on macrophage recruitment and 
activation coupled to a massive extracellular remodeling. 
 
Taken together, the data gathered in our lab in several in vitro and in vivo experimental systems strongly 
suggest the occurrence of an RNASET2-based intercellular cross-talk, whose molecular mechanisms are 
nevertheless largely unknown. 
 As a first step in the logical sequence of events culminating in the above mentioned RNASET2 biological 
activities, we hypothesized the occurrence of a putative receptor for RNASET2. 
The common idea behind all our approaches was to covalently link RNASET2 (either the endogenous 
protein or the human recombinant protein) to any interactor and, after purification of the complex, to 
perform a MS analysis to characterize the interactants. 
As a first approach, we carried out chemical modification of purified recombinant RNASET2 with different 
compounds (SDA, LC-SDA, Sulfo SDA, Sulfo LC-SDA) in order to add a diazirine ring to all primary ammines 
of the target protein. The resulting modified RNASET2 protein could then, in principle, be crosslinked to 
all electron donors available following UV light activation. The modified protein was then incubated with 
RNASET2-silenced OVCAR3 cells and analyzed by western blot following UV exposure. Despite several 
attempts with this approach, we could not observe any shift in the molecular weight of RNASET2. 
As a second approach, parental OVCAR3 cells expressing RNASET2 were cultured in a medium containing 
photo-reactive amino acids, making the modified proteins prone to UV-crosslinking but, even with this 
approach, we failed to see any detectable shift in the molecular weight of RNASET2. 
Considering that most of the result obtained show evidence of a tropism of RNASET2 for cells belonging 
to the monocyte/macrophage lineage, with our last approach tested a promyelocytic cell line. We 
exposed the U937 cells preincubated with rRNASET2 to a chemical crosslinkers (BS3) able to covalently 
link two or more proteins in close proximity. By this approach we managed to see a shift in the molecular 
weight of the RNASET2, but unfortunately in the next step we couldn't purify any detectable complex. 
 
There are many reasons that could explain our failures: 
? An RNASET2 receptor might not exist although in our last attempt we cannot definitively exclude 
its existence.  
? The putative RNASET2 receptor might expressed at very low levels, hence the WB technique might 
not be sensitive enough to detect it. To solve this problem, we could scale up the system or work 
with membrane enriched samples.  
? The covalent modification produced by the chemical crosslinkers might produce a complex that 
is no more recognizable by the antibody used in the WB or purification step. A possible solution 
in order to overcome this problem consists in performing a classical IP over a membrane enriched 
extract and, to further reduce the detection problems, proceed with MS analysis over the whole 
SDS-gel lane. 
? Finally, recent experiments conducted by our collaborators provide evidence that RNASET2 might 
be present inside extracellular vesicles (exosomes). This result opens new opportunities of 
research and might change our prospective about the mechanism behind RNASET2 sensing 
and trafficking. 
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Considering that TAMs are usually forced by the tumor cells to acquire an M2-polarized pro-tumorigenic 
phenotype, a key finding of our research group is that tumor xenografts that are suppressed in 
their growth following RNASET2 overexpression display a strong infiltration of M1-polarized macrophages 
[Acquati, 2011, 2013], which are known to show anti-tumorigenic properties. Therefore, the last part of 
this PhD program was dedicated to investigate the molecular/cellular bases of the interaction between 
RNASET2 and immune cells, in particular to describe a possible involvement of this protein in driving 
macrophages polarization. 
The main idea was to develop a system to reliably produce M0, M1 and M2 macrophages that could then 
be used to test the effect of RNASET2 looking at their transcriptional profile.  
To this end, we chose a well-known cellular model (THP-1 cell line) and, in order to remove any bias from 
future analysis, we selected a pool of cells silenced for the expression of RNASET2. 
THP-1 is a promyelocytic cell line therefore in order to effectively produce polarized cells we needed to 
differentiate it into macrophages. Using the guidelines found in the literature we managed, by treating 
THP-1 cells with PMA 5 ng/ml for 48 h, to produce M0 macrophages.  
Subsequently, we developed a protocol to effectively drive naive macrophages to either M1 or M2 
phenotype. We followed the suggested guidelines and assessed the efficacy of our system by testing a 
small panel of known marker of polarization (TNF, CXCL10, CCL19 for M1 polarization and CCL22, MRC1, 
MSR1 for M2 polarization). 
Considering the final aim of the developed assay, we tested whether our macrophages, especially M1 and 
M2, still retained the plasticity to change their profile according to external stimuli. M0 cells were exposed 
to both M1 and M2 stimuli; the resulting profile was neither M1 nor M2, suggesting that the cells prepared 
with our system still retained the characteristic/desired plasticity to properly respond to external signals.  
The data gathered so far support the idea that the system developed might be useful to study the 
involvement of RNASET2 in macrophages polarization. 
 
To summarize, during these three years of my PhD program I was involved in many different parts of a 
project aimed at deepen our understanding of the mechanism underlying RNASET2 tumor suppression. 
Although I wasn't able to identify any putative receptor for RNASET2 experimental evidence suggests the 
existence of a molecular mechanism involved in the “sensing” of the RNASET2 protein. Further studies are 
clearly needed in order to clarify this issue and the recent finding of RNASET2-containing exosomes is a 
promising avenue of investigation.  
 
The data collected in Hirudo strengthen our hypothesis of a close relationship between Immune cells (in 
particular cells belonging to monocyte/macrophages lineage) and RNASET2 but, more importantly these 
results open new research opportunities to study the involvement of T2 ribonucleases in inflammation. 
From a strictly technical point of view, I was able to improve the system of production and purification of 
the recombinant human protein, making it possible the use of RNASET2 in conditions previously 
inaccessible (interaction with immune cells/injection in organism).  
To conclude I contributed to laid the bases for future studies aiming at dissecting the involvement of 
RNASET2 in macrophages polarization and I did it by developing a simple assay that might test the 
"polarizing potential" of RNASET2 (but potentially of any compound). 
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Concluding remarks 
 
In January 2016, through the help of my tutor, Prof. Roberto Taramelli, I had the opportunity to move to 
the USA in the laboratory of Prof. Sui Huang at the Institute for Systems Biology, Seattle WA. Here, for 10 
months, I gained familiarity with the exploitation of computational tools to answer biological questions 
and I have also been exposed to the emerging field of computational/systems biology. 
The central role of genetic mutations as the driving force for tumorigenesis and tumor progression is 
challenged by the increasing recognition of cell population heterogeneity and plasticity, which can 
generate different phenotypes from a single genome [Zhou, 2016]. The main research interest of Prof 
Hung’s lab is to address the origin(s) of heterogeneity and in particular what are its consequences for 
tumor development. During this period, I have been involved in and contributed to three different 
projects: 
 
The first project was focused on the understanding of the role of adaptation in cancer drug resistance. 
When cancer cells fail to respond to chemotherapy regimes the usual explanation focuses on the presence 
of inherently resistant cells produced by random mutations, which are then selected for.  
However, within the framework of the population heterogeneity and cell plasticity, the resistance 
phenotype can be acquired exploiting physiological cellular programs [Chang, 2008].  
Among them one that is gaining much attention is the cellular stress response adaptation following 
chemotherapy or irradiation. The basic hypothesis is that the treatments are indeed inducing the tumor 
cell to enter a stress response state which in turn protects them from the noxious agent [Huang, 2009, 
2010]. 
I used the leukemic HL60 cell line as the cancer model and I studied the response of the cells to Vincristine 
treatment. 
In order to assess how the emerging phenotype (the drug resistance) was induced following treatment, 
we analyzed a population of treated cells at the single cell level. To address this issue, I learnt a new 
technique called single cell qPCR which allows to quantify the gene expression profile from a single cell. 
Furthermore, the single cell resolution allows to study the occurrence of the rare and underrepresented 
cells within a given population. 
Preliminary results show the emergence of a subgroups of cells, within the main population, characterized 
by the expression of stemness markers and further analyses are required to demonstrate whether these 
cells are associated with the emergence of drug resistance. 
 
The second project was aimed at the development of an assay to estimate the proliferation rate of a single 
cell culture in a longitudinal study; in particular, I developed a pipeline that allows to measure the area 
occupied by cell in every well of a 384-wells plate for each defined time point. 
Previous observations using an in vivo model suggested that the per capita growth rate of the cell is 
dependent on the cell density (Allee effect) [unpublished data]. Within this conceptual frame, we were 
interested in collecting data that could support a new model to describe the cell proliferation also in 
vitro. 
In the first two months of work I developed the pipeline for the analysis as follows:  
? I have written the script to control the acquisition of a grid of images and iterate the process for 
every desired well in a 384-wells plate. 
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? I have also written a script in ImageJ that can stitch together the grid for each well and produce a 
single image and another script that measures the cell in an image. The “area occupied by the 
cell” is the variable analyzed in order to test our model. 
As a first experiment I measured the growth rate of different cultures starting with different cell numbers: 
1 cell, 4 cells, 10 cells (80 wells per each condition). The result shows that cells plated at the density of 10 
cells have a more consistent behavior and a per capita growth rate higher than cells plated at lower initial 
density (4 and 1 respectively). We are currently building a mathematical model that could fit and explain 
the gathered data. 
 
The third project I contributed to was focused on the analysis of the dysregulation of the chemokine-
cytokine and cognate receptors expression in different cancer tissues. We used a database of 2536 know 
chemo-cytokines/cognate receptors interactions and the data were collected from The Cancer Genome 
Atlas (TCGA) database. The basic idea was to assess whether and how the communication provided by 
the ligand receptor interaction is changed in cancer compared to normal tissues. 
We focused on the pairwise analysis of the correlation of the expression of the ligand (chemo-cytokine) 
versus its receptor. 
The main observation is that in cancer tissues there’s a general loss of correlation, either positive or 
negative with respect to normal tissues. This finding might depict cancer as a “less communicative” entity, 
which is not able to react properly to certain stimuli, especially from the ligand receptor interactions we 
decided to assess.  
Since the TCGA data are retrieved from bulk RNA samples, it is not possible to define the exact 
composition in term of cells type; the only information available in this sense is the percentage of 
infiltrating immune cells. Knowing that most of the ligand receptor interaction are mainly mediated by 
immune cells we checked whether our previous finding is a genuine feature of cancer cells, or a side-effect 
due to a different percentage of infiltrating immune cells.  
Interestingly, clustering the samples by percentage of infiltrating immune cells do not affect the overall 
distribution of the correlation; this allow us to infer that the observation of a different distribution of 
correlation is a true feature of the cancer cells (or at least is not driven by the percentage of infiltrating 
immune cells).  
An interesting question we tried to investigate is whether it is possible to define (or at least suggest) “who 
talks with who” in term of different cell type. As mentioned before the TCGA data are a large source of 
information but these data are averages of the expression of all the different cells that make up a tissue; 
this means that is not possible the associate the value of expression to any specific cell type. Therefore, 
in order to address this question, we used single cell RNAseq data from melanoma samples (19 different 
patients) recently published [Tirosh, 2016].  
Single cell RNAseq data allow to quantify the expression of different genes from just one cell. Having a 
single cell level resolution is critical from certain viewpoints, especially if the goal is to understand the 
heterogeneity of a system or to identify very rare subpopulations.  
In our case single cell data were useful because we were able to measure the expression of ligands and 
receptors from virtually pure tissues inside the same sample. 
As criteria for the present analysis we assumed that the cells (among all the others inside the sample) with 
a significant higher expression of a specific ligand are defined “major broadcasters” (for that specific 
ligand), and the cells with a significant higher expression of a receptor are defined “major receivers”. Our 
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hypothesis is that if we assume a communication between cells, then is more likely that the major 
broadcasters would “talk” to the major receivers.  
Given that assumption and focusing on interactions from cancer cells or towards them, we were able to 
define a higher cross-talk between CAF or endothelial cells (rather than immune cells) with cancer cells.  
This result, although preliminary, is promising and could be exploited in more targeted experiments in 
order to better understand the crosstalk between cancer cells and the single cells comprising the 
microenvironmental populations.
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